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Hypertension is a leading risk factor for cardiovascular morbidity and premature death. 
Prevalence of hypertension in the adult population in Sweden has been estimated to 27%. 
Atrial fibrillation (AF) is the most prevalent sustained arrhythmia of clinical relevance with 
an estimated prevalence of at least 2.9% among adults in Sweden. Similarly to hypertension, 
AF is independently associated with an increased risk for cardiovascular morbidity and with a 
two-fold increased risk of death. The underlying mechanisms responsible for this association 
however, are not fully known. Both conditions may impose a heavy burden upon affected 
patients as well as on the health care system. AF and hypertension are closely intertwined and 
often coexist. Hypertension is the major risk factor for AF development and conversely, AF 
affects blood pressure (BP). The irregular heart rhythm in AF is one factor influencing BP, 
but also other factors may play a part. Furthermore, the presence of AF has implications for 
conventional BP measurement. AF-related effects on BP are studied to a very limited extent. 
Possibly, AF-induced BP effects may have pathophysiological consequences and may also 
influence BP measurement accuracy. Consequently, these factors may negatively influence 
risk assessment and prognosis in patients with AF. 
The aims of this thesis were 1) to systematically quantify beat-to-beat BP variability in 
patients with AF compared to sinus rhythm (SR); 2) to study how BP, as measured with 
different techniques, is affected by the presence of AF; 3) to investigate the relationship 
between peripheral and central intra-arterial BP, in patients with AF compared to SR; 4) to 
evaluate the accuracy of conventional BP measurement in relation to peripheral and central 
intra-arterial BP, in patients with AF and compared to SR.  
Methods and results 
In the prospective study I, patients scheduled for a coronary angiography were recruited. 
Participants included 21 patients in AF and 12 patients with SR. Intra-arterial BP was 
recorded from the radial and brachial artery and from the ascending aorta. The primary 
outcome measure was beat-to-beat BP variability, defined as average systolic and diastolic 
BP difference between consecutive beats, at each site of measurement. A significant 
difference (p<0.001) in BP variability, in AF compared to SR, was observed for all locations 
of measurement. Systolic BP variability was roughly doubled in patients with AF (4.9 vs 2.4 
mmHg), whereas diastolic BP variability was approximately six times as high (7.5 vs 1.2 
mmHg) in patients with AF compared to SR. 
Study II was a retrospective registry analysis based on data from electronic medical records. 
487 patients, treated with electrical cardioversion (ECV) for persistent AF, were included in 
the study. Information regarding auscultatory sphygmomanometric BP and rhythm, on the 
day before and 7 days after ECV, was obtained. The primary outcome measure was BP 
change in patients with restored SR after ECV. In this group with restored SR, systolic BP 
increased by 9 mmHg (p<0.01), whereas diastolic BP decreased by 3 mmHg (p<0.01). 
 
 
Furthermore, the proportion of patients with a hypertensive BP-level (≥140/90) increased by 
40% in this group. 
In study III, 98 patients with persistent AF undergoing ECV were prospectively recruited. BP 
was evaluated with 24-h ambulatory BP monitoring before and approximately one week after 
ECV. The primary outcome measure was BP change in patients with restored SR after ECV. 
Among 60 patients maintaining SR, mean systolic 24-h ambulatory BP increased by 5.6 
mmHg (p<0.001) and mean diastolic 24-h ambulatory BP decreased by 4.7 mmHg 
(p<0.001). Accordingly, a 10.4 mmHg (25%) increase in pulse pressure was observed among 
patients with restored SR. 
Study IV comprised the same individuals as study I. Conventional BP (auscultatory 
sphygmomanometric and automated oscillometric) and intra-arterial BP was measured 
simultaneously. The first aim was to investigate how intra-arterial BP changes throughout the 
arterial tree in patients with AF in comparison to patients in SR. The second aim was to 
evaluate the accuracy of conventional BP measurement in patients with AF in comparison to 
central and peripheral intra-arterial BP, and in comparison to patients in SR. BP changes 
throughout the arterial tree was similar in patients with AF compared to SR. Conventional BP 
was in general very accurate in comparison to diastolic intra-arterial BP, both in AF and SR. 
In patients with AF, oscillometric blood pressure overestimated systolic intra-arterial brachial 
(4.1 mmHg, p=0.07) and central (5.0 mmHg, p=0.04) BP. With measurement bias in SR 
taken into account, oscillometric BP over-estimated systolic intra-arterial brachial BP by 14.1 
mmHg (p<0.01) and central BP by 9.0 mmHg (p=0.01) in patients with AF. 
Conclusions 
Beat-to-beat BP variability is increased in patients with AF compared to SR. According to the 
results from studies in this thesis, systolic BP is lower and diastolic BP is higher in AF 
compared to SR, as measured by auscultatory sphyghmomanometry or by oscillometric 24-h 
ambulatory BP monitoring. As a consequence, pulse pressure is markedly lower in AF 
compared to SR. Intra-arterial BP change throughout the arterial tree is similar in patients 
with AF and SR. Conventional BP measurement was accurate in relation to diastolic intra-
arterial BP, but oscillometric BP measurement overestimated intra-arterial brachial and 
central systolic BP in patients with AF, in particular when compared to patients in SR. 
The presence of AF affects BP. This may have implications for the accuracy of conventional 
BP measurement and may possibly also have pathophysiological consequences. Suboptimal 
understanding, measurement and treatment of BP may negatively influence prognosis in 
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1 RESEARCH QUESTION AND RATIONALE 
 
Atrial fibrillation (AF) is common and the prevalence in Sweden has been estimated to be at 
least 2.9% among the adult population.1 Hypertension is even more frequent with prevalence 
estimates ranging from 20-50%.2–4 AF is independently associated with increased 
cardiovascular morbidity and mortality,5,6 whilst hypertension counts as the leading risk 
factor for premature death.3,4 Blood pressure (BP), hypertension and AF are closely 
intertwined.2 Hypertension is a major risk factor for AF developement7,8 and consequently, 
AF and hypertension very frequently coexist.2,9 Conversely, AF affects BP10 and BP 
measurement accuracy.11 However, whereas the impact of AF on BP measurement accuracy 
is studied to some extent, the AF-related effects on BP itself are only studied to a very limited 
extent. Possible pathophysiological and clinical consequences of such AF-related effects on 
BP are barely studied at all. It is unknown what constitutes an optimal BP level for AF 
patients since this is not specifically and prospectively studied.2,12 AF rhythm may 
potentially, in itself, be causally linked to the observed increase in cardiovascular morbidity 
and mortality.13 However, underlying pathophysiological mechanisms responsible for such a 
possible causal connection are unknown. Thus, several aspects regarding the interplay 
between AF, blood pressure and hypertension is insufficiently studied, and its importance 
may be underappreciated. 
In this thesis some yet unanswered research questions pertaining to BP in AF were addressed. 
We aimed in particular to study how AF may affect BP and to evaluate how the presence of 





2.1 WHAT IS BLOOD PRESSURE? 
Blood pressure is an elemental physiological parameter, used in everyday clinical practice. 
However, in clinical practice, blood pressure (BP) is often merely perceived as being a peak 
systolic and a nadir diastolic value, non-invasively measured in millimeters of mercury 
(mmHg) from a conduit artery (usually the brachial artery). From a research perspective it is 
thus important to consider how BP is more complex than this. BP may best be conceptualized 
as a continuous pressure-curve (see figure 1) from which several other parameters, in addition 
to systolic and diastolic BP, may be derived. 
 
 
Figure 1. Intra-arterial blood pressure recording from patient in sinus rhythm. 
 
The pressure curve changes over time (short- and long-term) and depending on the location 
of measurement. It is also important to consider that blood pressure and blood flow has a 
pulsatile component because of the nature of the pump (the heart), as well as a steady 
component.14 The steady pressure component is represented by the mean arterial pressure 
whereas the pulsatile pressure component is represented by systolic and diastolic pressure.14 
The elastic properties of large arteries have important implications for the BP waveform. The 
energy released from the left ventricle into the arterial system with every systole is, through 
the elasticity of large arteries, partly stored, only to be released as kinetic energy during 
diastole and thus partly transforming pressure and flow from pulsatile to a more continuous 
one.15 As with the rest of the human body, arteries age over time, thus losing some of its 
elastic ability, referred to as arterial stiffening.16,17 This process in turn affects BP in so forth 
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that systolic BP increases whereas diastolic BP decreases from middle age and onwards.18 
Disease processes such as hypertension affect the properties of arteries and the process of 
arterial stiffening.16,19  
Another important concept that needs mentioning is that of reflected waves.20 The BP wave is 
reflected at various sites in the arterial tree, causing a reversed pressure-wave that is directed 
from the periphery towards the heart. This reflected pressure wave acts as a pressure 
amplifier, in particular increasing systolic BP to different degrees along the arterial tree.15,21 
One consequence of this is often referred to as arterial pulse pressure amplification,21 i.e., the 
phenomenon that systolic pressure and pulse pressure increase from central to peripheral 
arteries. 
 
2.2 ELEVATED BLOOD PRESSURE - HYPERTENSION 
Blood pressure is a continuous physiological parameter and the threshold for when it is too 
high in a certain individual is not clear-cut. The different categories of BP according to the 
European Society of Cardiology (ESC) guidelines on hypertension22 is presented in table 1. 
 
 
Table 1. Different categories of blood pressure, according to the European Society of 
Cardiology. 
 
The most used definition for the clinical diagnosis of hypertension is a sustained resting 
office BP ≥140/90 mmHg, which is the definition also used by the ESC.22 This of course, is 
an arbitrary threshold and may be viewed as the BP level over which intervention (life style 
intervention and in most cases pharmacological intervention) can be expected to be beneficial 
for the individual in question. This BP threshold is derived from a plethora of large 
randomized clinical intervention trials, as are the evidence regarding the benefits from 
therapeutic intervention in hypertensive patients.23–26 Of note, BP-levels below the threshold 
for hypertension are categorized as high normal (130-139/85-89 mmHg) or normal (120-
129/80-84 mmHg), whereas optimal BP is defined as <120/80 mmHg. This implies that 
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although a BP level of 120-139/80-89 mmHg may not warrant pharmacological intervention, 
it may still not be an optimal BP-level with regard to long term risk for cardiovascular 
morbidity. This is also reflected in the 2017 ACC/AHA hypertension guidelines in which 
hypertension is defined as BP ≥130/80.27 With this definition, 46% among all US adults and 
up to 63% of those aged 45-75 are defined as hypertensive.28,29 
The underlying mechanisms responsible for the development of hypertension are 
multifactorial, and include life style factors as well as genetical disposition.30,31 An 
unphysiologically elevated blood pressure over time harms the arterial endothelium,32 
increasing the risk for atherosclerosis and its potential deleterious effects.33 Hypertension is 
the leading global risk factor for premature death.30,34,35 Prevalence is high and according to a 
report from 2004 by the Swedish agency for health technology assessment and assessment of 
social services (SBU), 27% of the adult population has hypertension. Globally, estimates of 
hypertension prevalence in different regions ranges from 20-50%.2–4 
 
2.3 BLOOD PRESSURE MEASUREMENT 
As described above, BP changes over time and throughout the arterial tree. Thus, a single 
blood pressure measurement is an estimate of the BP at a specific point in time at a certain 
arterial location. Furthermore, for all methods of measurement, there is a potential for 
measurement bias.  
The original, clinically useful, method for BP measurement was developed by Riva-Rocci in 
the late 19th century and the method was later improved by the addition of the use of 
Korotkoff sounds.36,37 With this method, a mercury or aneroid sphygmomanometer and a 
stethoscope is used38 and this has been the predominant way of measuring BP, at least up till 
recently.  
With the oscillometric method, pressure waveforms are derived from oscillations in the artery 
(usually the brachial artery), which is then analyzed to estimate BP. Automatic oscillometric 
BP devices was introduced in the 1980s and has since been increasingly used in clinical 
practice.38–40 
Office BP usually refers to BP measured by a professional within health care, either with the 
manual auscultatory sphyghmomanometric or the automated oscillometric method.41 
Although several factors with potential to cause measurement bias exist in relation to manual 
auscultatory office BP, this has been the predominant method for BP measurement in 
randomized intervention trials.41 
A single BP measurement provides a snapshot estimate of BP at that specific point in time 
whereas the harmful effects of elevated BP is better reflected by the mean BP load imposed 
on central organs over longer periods time.42 To this end, various techniques to estimate mean 
systolic and diastolic BP over time has been developed. 24-h ambulatory BP monitoring, in 
which automated oscillometric BP is repeatedly obtained over 24 hours, is such a method 
which is widely used in clinical practice. It has been demonstrated that 24-h ambulatory BP 
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may be a better predictor than office BP in relation to cardiovascular outcomes.43–45 The 
golden standard for reference BP is to obtain intra-arterial BP recordings. Since this method 
is invasive it is however not feasible for most clinical scenarios.  
Conventional BP measurement (auscultatory sphygmomanometric or automated 
oscillometric) is normally obtained from the upper arm, i.e., the brachial artery. As 
mentioned, BP however change throughout the arterial tree.46 Central BP refers to BP in the 
central arteries such as the ascending aorta, whereas peripheral BP refers to the pressure in 
the brachial and more peripheral arteries. Central BP may better reflect the true blood 
pressure load imposed on central target organs such as the heart and the brain.47–49 In most 
individuals, diastolic and mean arterial pressure are essentially unchanged throughout the 
arterial tree, whereas systolic BP increases the more peripheral the site of measurement.15,21 It 
has however been proposed that there may be heterogeneity in this pattern with different 
identifiable phenotypes.50  
There are different methods for non-invasive estimation of central blood pressure.51 Since 
central BP theoretically should be a better predictor of cardiovascular outcomes than 
conventional peripheral BP, several studies have investigated these methods with regard to 
prognosis. However, the results of those studies are heterogenous and the superiority of non-
invasively obtained central BP over conventional BP has not been unequivocally shown.52–54 
Conventional, peripheral BP measurement thus estimates brachial BP, with a certain 
(normally unknown) measurement bias. This estimate in turn, could arguably be conceived as 
a proxy for central BP, which on theoretical grounds should be the BP comprising the most 
useful data for clinical decision making. However, in the large randomized therapeutic 
hypertension trials, the predominant method for BP measurement has been conventional 
office BP. Thus, although concerns against conventional office BP measurement may be 
raised, this is the method upon which the lion’s share of current scientific evidence for when 
and how to treat hypertension is based. 
 
2.4 WHAT IS ATRIAL FIBRILLATION? 
The underlying pathophysiological mechanisms responsible for the development and 
progression of AF are complex and not fully understood. However, it involves structural and 
electrical remodeling.55–57 Structural remodeling refers to the anatomical changes that may be 
observed in the atria, such as fibrosis, hypertrophy and dilatation. Electrical remodeling refers 
to processes that affect ion channels and thereby affect depolarization patterns in the atria.55,58 
In SR, depolarization is initiated in the sinus node and the depolarization of the atria occurs in 
an organized manner. In AF, the sinus node remains inactive and there is constant 
uncoordinated depolarization and repolarization of the atria. In contrast to SR, where heart 
rate is normally controlled by the pace of the sinus node, (ventricular) heart rate in AF is 
primarily governed by the conduction status of the AV node. As a consequence of these 
prevalent conditions, heart rhythm in AF is irregular and often faster in comparison to the 




Figure 2. ECG strip from patient in atrial fibrillation. 
 
Another hemodynamic consequence of AF is the loss of synchronized atrial contraction at the 
end of diastole, potentially decreasing left ventricular filling and stroke volume.59,60 On a 
group level, AF is associated with a deterioration of hemodynamic parameters, such as 
cardiac output and left ventricular filling pressure.61 A number of factors may contribute to 
impairment of hemodynamics in AF. Loss of synchronized atrial contraction, increased 
ventricular heart rate, increased R-R-variability and neurohormonal effects may all play a 
part.61,62 Restoration of SR is associated with improved hemodynamic parameters.60 
AF is the most common arrhythmia of clinical relevance and it has an estimated prevalence 
of at least 2.9% among adults in Sweden.1 The incidence increases with age and the 
prevalence is over 10% in those over the age of 80 years.1 As for cardiovascular disease in 
general, AF is more frequent and debuts at a younger age in men compared to women.63 
Except for gender and age, common cardiovascular risk factors such as hypertension, obesity 
and diabetes are also risk factors for the development of AF.63,64 With an aging population 
and an increasing prevalence of AF risk factors, a trend for increasing AF incidence is 
believed to continue65 and AF prevalence is projected to double within this century.65,66 
Without preventive anticoagulant therapy, individuals with AF in general run a five-fold 
increased risk for stroke.5,6 Although direct hemodynamic effects of AF, such as loss of 
synchronized atrial contraction, is important for the risk of stroke, other effects on the 
endothelium and on the coagulative properties of the blood probably also play a part.67  
AF is associated with an increased cardiovascular morbidity and mortality, which may only 
to a lesser part be explained by the increase in the risk for stroke.5,68 Results from several 
studies imply a two-fold increase in the risk for mortality in patients with AF compared to 
patients with SR.5,68 Since AF shares most of its risk factors with other cardiovascular 
disease, possible direct causal relationships between AF and increased cardiovascular 
morbidity have been difficult to determine. 
Symptoms of AF include shortness of breath, palpitations and reduced exercise capacity.64,69 
For symptomatic patients, different methods are used to restore or maintain SR. Electrical 
cardioversion (ECV), in which a sedated patient receives a high energy electric shock, is 




2.5 BLOOD PRESSURE AND HYPERTENSION IN ATRIAL FIBRILLATION 
In AF the heart rhythm is irregular. During diastole, arterial BP progressively falls until the 
start of the following systolic left ventricular contraction. A longer R-R-interval results in a 
more pronounced fall in BP during diastole. At the same time, a longer diastole increases left 
ventricular filling, resulting in increased stroke volume and increased blood pressure surge 
during the following systole. As a consequence, there is an increase of beat-to-beat BP 
variability in AF compared to SR (see figure 3).10,70  
 
 
Figure 3. Intra-arterial blood pressure recording from patient in atrial fibrillation. 
 
This phenomenon has implications for BP measurement in AF. A single conventional office 
BP only provides a single systolic and diastolic BP value from a number of different systolic 
and diastolic pressures during the BP measurement. Because of this rhythm irregularity, 
auscultatory BP measurement is often perceived as more difficult and uncertain in AF than in 
regular sinus rhythm.11 Furthermore, there is no accepted universal reference standard for BP 
measurement in AF.71 Earlier studies evaluating the accuracy of oscillometric BP 
measurement in AF, mostly using auscultatory sphyghmomanometric BP as reference 
method, are not conclusive.72–75 The topic of how to accurately measure BP in the presence of 
AF is still debated.76,77 Triplicate measurements are usually recommended and some authors 
recommend to continue the use of the auscultatory method in clinical practice.78 
On a population level, hypertension is the most common risk factor for the development of 
AF.7,8 Hypertensive patients run an increased risk of incident AF and this risk increases with 
increasing BP.63,79–81 Patients with BP in the high-normal range also have an increased risk 
for incident AF.82,83 Accordingly, approximately 15% of individuals with hypertension have 
concomitant AF84 and hypertension prevalence in patients with established AF may be as 
high as 60-80%.2,9 In addition, concomitant hypertension further increases the risk for AF 
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complications such as heart failure, stroke and bleeding.64 According to the recently 
published guidelines for AF by the ESC, in most patients, AF should be regarded as a 
manifestation of hypertension target-organ damage.64 ESC guidelines for hypertension and 
atrial fibrillation recommend that pharmacological treatment of hypertension, regarding both 
thresholds for initiation and BP treatment goals, should be no different in patients with AF 
than for other patients with hypertension.22,64 However, since patients with AF have been 
systematically excluded from randomized hypertension treatment trials,11 the underlying 
evidence for these recommendations are quite thin. 
The underlying pathophysiological processes linking hypertension with the development of 
AF are not fully known but hemodynamic and structural effects are probably involved. 
Hypertension may cause left ventricular diastolic dysfunction, leading to elevation of left 
atrial pressure and thus inducing remodeling of the left atrium and thereby providing a 





The overall aim of this thesis was to evaluate how the presence of AF may affect BP and the 
accuracy of conventional methods for BP measurement. 
The specific aims of the studies were: 
Study I: To systematically quantify beat-to-beat BP variability in patients with AF compared 
to SR. 
Study II: To study how BP, as measured with auscultatory sphygmomanometry, is affected 
by the presence of AF. 
Study III: To study how BP, as measured with oscillometric 24-h ambulatory BP 
monitoring, is affected by the presence of AF. 
Study IV: To investigate the relationship between peripheral and central intra-arterial BP, in 
patients with AF compared to SR. To evaluate the accuracy of conventional BP measurement 




4 MATERIALS AND METHODS 
4.1 STUDY I AND IV 
4.1.1 Ethical considerations 
Studies I and IV comprised the same individuals. Invasive procedures such as peripheral and 
coronary artery catheterization always carry a risk for complications. Furthermore, patients 
undergoing an invasive procedure may experience discomfort and sometimes pain. Patients 
participating in the study were already scheduled for a coronary angiography by clinical 
indication. It was deemed that the marginally prolonged procedure, necessary for the BP-
recordings in the study, would also only marginally prolong potential feelings of discomfort 
or pain in study persons. The addition to a routine coronary angiography were short pauses 
with the catheter resting during the beginning of the procedure, and therefore the risk for 
medical complications was not expected to be increased by participating in the study. Thus, it 
was deemed that the scientific benefits of conducting the study would outweigh the potential 
risk of harm for participants. The study was in accordance with general good clinical practice 
(GCP) and all participants signed a written informed consent. The study was approved by the 
Regional Ethics Committee, registration number 2011/788-31. 
4.1.2 Study design and participants 
In this prospective study, patients referred for routine coronary angiography with right radial 
artery access, either with persistent AF or SR, were screened for participation. Patients below 
18 years of age, with ongoing chest pain and/or ischemia, persisting atrial flutter, left 
ventricular ejection fraction <30%, hemodynamically significant valvular heart disease, BP 
difference between right and left arm >20 mmHg or known significant arterial anomaly, were 
excluded from participation. Patients treated for acute coronary syndrome without evidence 
of ongoing ischemia were eligible for participation. All patients were examined with 
echocardiography within the last year of enrollment. Data regarding background clinical 
characteristics were obtained from the digital medical record and directly from participants. 
4.1.3 Data recording procedure 
Right and left upper arm sphygmomanometric and oscillometric office BP were obtained on 
the same day but prior to coronary angiography. Left upper arm circumference was measured 
and appropriate cuff size was used. BP measurements were performed after at least five 
minutes of rest in the supine position. After routine preparations for coronary angiography, 
right radial artery access was established using six French (6F) sheaths and 5F standard 
diagnostic catheters for all patients. We used adjustable level pressure sets for continuous 
recording of intra-arterial BP. The pressure transducer was adjusted to match the height of the 
radial introducer sheath after zeroing arterial pressure to air. 
Intra-arterial pressure recordings were obtained using pressure transducer-equipped 
manifolds (NAMIC®, Navilyst Medical Inc, Marlborough, MA, USA), connected to the 
RadiAnalyzer Xpress® unit (St Jude Medical, St Paul, MN, USA) for digital storage. Intra-
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arterial recordings included at least 15 heart cycles. For conventional BP measurements an 
upper arm cuff of appropriate size was used. The right and left upper arm were adjusted in 
height so that they matched the estimated height of the left atrium. Figure 4 is a schematic 
illustration of the BP measurement procedure. 
 
 
Figure 4. Flow-chart for conventional and intra-arterial blood pressure measurements 
procedure. 
 
Oscillometric BP measurements were performed using a Philips Easy Care Adult cuff 
connected to Philips IntelliVue MMS X2 bedside monitoring system (Philips Healthcare, 
Andover, Ma). The first intra-arterial recording was obtained from the right radial artery 
introducer sheath. Directly afterwards, oscillometric BP (OBP) from the upper right arm was 
obtained. Thereafter, the pressure transducer was adjusted to estimated left atrial level and the 
diagnostic catheter was advanced to the brachial artery. Intra-arterial brachial BP and upper 
left arm manual sphygmomanometric BP (MBP) were then recorded simultaneously. In a 
similar manner, intra-arterial brachial BP and upper left arm oscillometric BP (OBP2) were 
simultaneously recorded. Finally, the diagnostic catheter was advanced to the ascending aorta 
and simultaneous central intra-arterial and upper left arm oscillometric BP (OBP3) were 
recorded. Systolic and diastolic BP from conventional measurements were noted in the case 
report form whereas intra-arterial recordings were digitally stored (RadiAnalyzer Xpress® 
unit (St Jude Medical, St Paul, MN, USA)) for off-line analysis. 
4.1.4 Data analysis 
For intra-arterial BP the RadiView 2.2® software (St. Jude Medical, St Paul, MN, USA) was 
used for data analysis. Systolic and diastolic BP were manually determined from the intra-
arterial BP tracings. The absolute systolic and diastolic BP difference from one consecutive 
beat to the next, regardless of increase or a decrease in BP, was calculated from intra-arterial 
recordings. The primary outcome variable in study I, beat-to-beat BP variability, was defined 
as average systolic and diastolic BP-difference between consecutive beats. Maximum beat-to-
beat BP-difference was also determined. As an alternative measure of beat-to-beat BP 
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variability coefficients of variation (CVAR) were calculated for systolic and diastolic 
pressures. 
4.1.5 Statistical methods 
Normally distributed data are presented as mean (± standard deviation) or median (25th, 75th 
interquartile range) for non-normally distributed data. The Shapiro-Wilk’s test was used to 
test for normality of distribution. To test for differences between groups, independent sample 
t-test or the Mann-Whitney test (depending on distribution of data) was used for continuous 
data. For categorical data a Chi square test or Fishers exact test was used. A Paired Samples t-
test was used to test for differences within groups. A One-Way ANOVA test was used to test 
for differences in beat-to-beat BP variability between locations. P-values <0.01 (Study I) or 
<0.05 (Study IV) were considered significant. Statistical analyses were performed using 
SPSS Statistics, Version 22.0 and 25.0 (IBM Corp. Armonk, NY).  
 
4.2 STUDY II 
4.2.1 Ethical considerations 
Study II was a retrospective observational register study based on data extracted from digital 
medical records. As such, patients included in the study were not asked permission for 
participation. In the process of data collection, the researchers involved in the study accessed 
and read individual medical records. This constitutes a potential breach of integrity on behalf 
of participating study persons and furthermore, no additional direct individual benefit was to 
be expected for participants. However, the potential benefits of conducting the study, for 
patients with AF in general, were deemed to outweigh the ethical problem of integrity. The 
Regional Ethics Committee deemed from the application (registration number 2014/2199-31) 
that the project as such, did not fall under the law for ethics approvals, but further deemed 
that they could not identify any ethical obstacles for the carrying through with the project. 
4.2.2 Study design and data collection 
Data from the digital medical records of 487 unique patients with persistent AF, undergoing 
electrical cardioversion at Södersjukhuset during 2013-2014 was collected and analyzed. A 




Figure 5. Flow-chart of inclusion process. Reprinted courtesy of Journal of Clinical 
Hypertension 2019;21:363-368. Wiley Periodicals, Inc.© DC indicates direct current. 
 
According to local clinical routine, patients scheduled for elective cardioversion had a nurse 
appointment the day preceding cardioversion (day -1) when a 12-lead ECG was recorded and 
sphygmomanometric office BP was obtained. One week after ECV (day 7), patients had a 
follow-up visit with repeat 12-lead ECG and office BP measurement. BP measurements and 
ECG recordings were performed by nurses at the Cardiology outpatient clinic. The same staff 
and the same methods were used at both visits. Local clinical routine stipulated that BP was 
measured after at least five minutes of rest in the supine position, using the auscultatory 
method with an aneroid sphygmomanometer. At each visit, a single BP was noted in the 
digital medical record. Data on background clinical characteristic, medication and BP were 
collected from digital medical records whereas data on heart rate and rhythm were obtained 
directly from ECG-recordings. 
4.2.3 Statistical methods 
Descriptive data are presented as mean and standard deviation or median and interquartile 
range according to distribution of data. Comparison of categorical variables was made using 
the Fisher’s exact test. The Shapiro-Wilk test was used to test for normality for continuous 
variables. For normally distributed data, a Student’s t-test was used to test for differences 
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between groups. For non-normally distributed data, the Mann-Whitney U test and the 
Wilcoxon signed-rank test were used. P-values <0.01 were considered significant. Statistical 
analyses were performed using SPSS Statistics, Version 22.0 (IBM Corp. Armonk, NY). 
 
4.3 STUDY III 
4.3.1 Ethical considerations 
Apart from routine procedures such as office BP measurement and ECG-recordings, study 
participants underwent two 24-h ambulatory BP recordings, one before and one after ECV. 
Although 24-h ambulatory BP is generally recommended and frequently used, it may be 
associated with patient discomfort, disturbed sleep and sometimes pain. On the other hand, a 
thorough evaluation of BP by means of 24-h ambulatory BP monitoring, may provide 
additional medical data that is of benefit for the individual. It was deemed that an ethical cost-
benefit calculation weighed in favor of conducting study III. The study was in accordance 
with GCP, all study persons were thoroughly informed about the study and the nature of the 
procedures involved. All patients signed a written informed consent before inclusion. The 
study was approved by the Regional Ethics Committee, registration number 2012/1272-31. 
4.3.2 Study design and participants 
In this prospective study, patients without significant valvular heart disease, undergoing ECV 
for persistent AF, were eligible for inclusion. The study was conducted at three different sites; 
Södersjukhuset, Karolinska University Hospital and Danderyd University Hospital. A flow 
chart of the inclusion process is presented in Figure 6. 
 
 
Figure 6. Flow-chart for inclusion process. Courtesy of Journal of Hypertension. August 21, 
2020, published ahead of print. doi: 10.1097/HJH.0000000000002623. Wolters Kluwer 




At the first study visit, background clinical characteristics regarding lifestyle factors, medical 
history and medication were obtained from participants and from medical records. A 12-lead 
ECG was recorded and automated oscillometric and auscultatory sphygmomanometric office 
BP were obtained. On the second visit, which was scheduled within a week before planned 
ECV, a 24-h ambulatory BP measurement (SpaceLabs 90217a device; Spacelabs, 
Snoqualmie, Washington, USA) was conducted. BP measurements were made every 20th 
minute both during daytime (0600-2200h) and night-time (2200-0600h). On the third visit, 
scheduled seven days after ECV, an ECG-recording and a 24-h ambulatory BP measurement 
was repeated. Data regarding heart rate was obtained from 24-h BP monitorings. BP 
measurements in the study were performed either by trained research nurses or by the 
researchers involved in the study. Upper arm circumference was measured, and the 
appropriate cuff size was used for all measurements. 
4.3.3 Statistical methods 
Comparisons of categorical variables were made using Fisher’s exact test. Descriptive data 
are presented as mean and standard deviation. Independent-samples t-test was used for 
comparisons between groups and Paired-samples t-test for comparisons within groups. 
Correlations between dependent and independent variables were tested using linear 
regression analysis. P-values <0.05 were considered significant. Statistical analyses were 




5 RESULTS PER STUDY 
5.1 STUDY I 
Twenty-one patients in AF and 12 patients in the SR control group were included in the 
study. The two groups were similar with regard to age, prevalence of treated hypertension 
and left ventricular ejection fraction. Resting heart rate was numerically slightly higher in the 
AF group (71.1 ± 12.1 beats per minute) compared to the SR group (62.4 ± 9.2 beats per 
minute), although this difference was not statistically significant (p=0.06). Of note, baseline 
office systolic BP was numerically lower, whereas diastolic BP was numerically higher in the 
AF group compared to the SR group (128.7/82.9 versus 137.4/77.2 mmHg), these differences 
were however also not statistically significant. For all but one patient, known or suspected 
ischemic heart disease was the primary indication for coronary angiography. Five patients 
were treated for acute coronary syndrome.  
The primary outcome variable in study I was beat-to-beat BP variability in AF patients in 
comparison to patients with SR. Median systolic beat-to-beat BP change, grouped by AF or 
SR, is presented in figure 7. 
 
 
Figure 7. Systolic beat-to-beat BP variability in patients with AF and SR. Reprinted courtesy 
of Blood Pressure. 2018;27(5):249-255. The authors©. RA indicates radial artery, BA 





A significantly higher systolic BP variability in AF patients compared to SR patients was 
observed for all locations of measurement: (median, interquartile range) 4.3 (3.5-10.4) mmHg 
vs. 2.2 (1.4-2.8) mmHg at the radial artery level, 4.9 (3.8-7.6) mmHg vs. 2.4 (1.6-3.3) mmHg 
at the brachial artery level and 5.4 (3.6-7.3) mmHg vs. 2.7 (2.3-3.8) mmHg in the ascending 
aorta (p<0.001 for all comparisons). Systolic BP variability defined as CVAR was also 
significantly higher in AF compared to SR. Furthermore, maximum systolic beat-to-beat BP 
change was significantly higher in AF patients compared to SR patients at all locations of 
measurement. For diastolic BP variability, the absolute and relative difference between AF 
and SR patients was even more pronounced, see figure 8. 
 
 
Figure 8. Diastolic beat-to-beat BP variability in patients with AF and SR. Reprinted 
courtesy of Blood Pressure. 2018;27(5):249-255. The authors©. RA indicates radial artery, 
BA indicates brachial artery, AA indicates ascending aorta. 
 
Mean beat-to-beat BP variability in AF and SR groups respectively were: 7.4 ±2.2 mmHg 
and 1.1 ±0.4 mmHg at the radial artery level, 7.2 ±1.9 mmHg and 1.4 ±0.7 mmHg at the 
brachial artery level and 7.8 ±2.8 mmHg and 1.1 ±0.4 mmHg in the ascending aorta (p<0.001 
for all comparisons). Diastolic BP variability defined as CVAR as well as maximum diastolic 




5.2 STUDY II 
487 unique patients were included for analysis in the study. At day 7 follow-up, 198 (41%) of 
patients had relapsed into AF (AF-AF group), whereas 289 (59%) patients remained in SR 
(AF-SR group). Baseline clinical characteristics were largely similar between the groups 
except for a diagnosis of heart failure which was more common in the AF-AF group 
(although LVEF did not differ significantly between groups). The primary outcome variable 
was BP change after restoration of SR. The main results are presented in table 2. 
 
 
Table 2. Mean systolic and diastolic BP. Divided according to rhythm after ECV. Reprinted 
courtesy of Journal of Clinical Hypertension 2019;21:363-368. Wiley Periodicals, Inc.© 
 
A mean increase in systolic BP by 9 mmHg and a mean decrease in diastolic BP by 3 mmHg, 
following restoration of SR was observed (p<0.001 for both comparisons). In contrast, in 
patients with a relapse in AF (AF-AF group), no change in BP was observed. To test if these 
BP changes were independent of changes in antihypertensive and antiarrhythmic medication, 
a subgroup analysis consisting of patients without any such medication changes between the 
visit before and after ECV was performed. The results from the analysis of these 371 patients 
were largely consistent with those of the entire cohort. A 9 mmHg increase of systolic BP 
after SR restoration could be observed. Diastolic BP numerically decreased by 2 mmHg, this 
difference was however not significant (p=0.1). We then analyzed the proportion of patients 
with a hypertensive BP-level (≥140/90 mmHg) before and after ECV. In the AF-SR group, 
the number of patients with a hypertensive BP level increased from 115 to 161, representing 






5.3 STUDY III 
Of the 120 patients included in the study, 98 patients were included in the statistical analysis. 
A flow chart of the inclusion process is presented in Figure 4. At the second 24-h ambulatory 
BP measurement, 62 patients had retained SR after ECV (AF-SR group), whereas 36 patients 
had relapsed into AF (AF-AF group). The two groups were similar in terms of age. There was 
a predominance of male participants, a high prevalence of preexisting hypertension and a 
high usage of b-blocking agents in both groups. The main results of the primary outcome 
variable (change in 24-h ambulatory BP following restoration of SR) are presented in table 3 
and figure 9. 
 
 
Table 3. Ambulatory blood pressure monitoring (ABPM) before and after ECV. Reprinted 
courtesy of Journal of Hypertension. August 21, 2020, published ahead of print. doi: 





Figure 9. 24-h ambulatory BP before and after ECV. Bar upper margin represents systolic 
BP, lower margin represents diastolic BP and entire bar length represents pulse pressure. 
Reprinted courtesy of Journal of Hypertension. August 21, 2020, published ahead of print. 
doi: 10.1097/HJH.0000000000002623. Wolters Kluwer Health, Inc.© 
 
In the AF-SR group mean systolic 24-h ambulatory BP increased by 5.6 mmHg and mean 
diastolic 24-h ambulatory BP decreased by 4.7 mmHg (p<0.001 for both comparisons). In 
contrast, both systolic and diastolic 24-h ambulatory BP numerically slightly decreased in the 
AF-AF group. These changes however, were not statistically significant. Accordingly, pulse 
pressure was markedly increased (approximately 25%) in patients with restored SR 
(p<0.001), whereas no change in ambulatory PP was observed in the AF-AF group. To 
evaluate the possible correlation between baseline BP level and the observed BP changes in 
the AF-SR group, mean arterial pressure (defined as mean 24-h ambulatory diastolic BP + 
(mean 24-h ambulatory PP/3)) was plotted against ambulatory PP change. As demonstrated 






Figure 10. Correlation between relative change in pulse pressure after ECV and mean 
arterial 24-h ambulatory BP before ECV. Reprinted courtesy of Journal of Hypertension. 
August 21, 2020, published ahead of print. doi: 10.1097/HJH.0000000000002623. Wolters 
Kluwer Health, Inc.© PP indicates pulse pressure. 
 
Mean heart rate significantly decreased from 79.5 ±11.5 to 57.6 ±8.7 bpm after ECV, 
whereas mean heart rate was unchanged in the AF-AF group. In a linear regression analysis, 
change in systolic 24-h ambulatory BP in the AF-SR group was not significantly correlated 
with change in heart rate (adjusted R2 0.045), whereas a moderate correlation (adjusted R2 
0.43) for diastolic 24-h ambulatory BP and change in heart rate was observed. 
We then analyzed the proportions of patients with a hypertensive BP level (mean daytime 
ambulatory BP ≥135 mmHg systolic or ≥85 mmHg diastolic). Before ECV, 36% of patients 
in the AF-AF group and 31% of patients in the AF-SR group were hypertensive according to 
daytime ambulatory BP. Among remaining individuals, who were normotensive before ECV, 
the proportion of hypertensive individuals after ECV was slightly higher in the AF-SR group 






5.4 STUDY IV 
The 33 patients included in the analysis (21 with AF and 12 with SR) are the same as for 
study I and baseline characteristics are briefly described under results for study I.  
The first aim of the study was to evaluate the relationship between intra-arterial peripheral 
(radial and brachial) and central BP in patients with AF compared to patients with SR. These 
results are presented in table 4 and figure 11. 
 
 
Table 4. Peripheral and central intra-arterial BP in AF and SR. PP indicates pulse pressure. 





Figure 11. Peripheral and central intra-arterial BP in AF and SR. Bar upper margin 
represents systolic BP, lower margin represents diastolic BP and entire bar length represents 
pulse pressure. Brachial is mean from measurements Brachial 1 and 2. 
 
Systolic intra-arterial BP was numerically, albeit not significantly, lower in AF patients 
compared to SR patients for all locations of measurement. In contrast, diastolic intra-arterial 
BP was significantly higher in AF compared to SR patients for all locations of measurement. 
As a consequence, PP was markedly lower in patients with AF compared to SR. In both 
groups, intra-arterial systolic BP was numerically lower, whereas diastolic BP was higher the 
more proximal the location of measurement. These BP-changes from peripheral to central, 
along the arterial tree were however very similar in the AF compared to the SR group and no 
significant in-between differences regarding intra-arterial systolic (p=0.6), diastolic (p=0.6) or 
PP (p=0.6) were observed. 
The second aim of study IV was to evaluate the accuracy of conventional BP measurement 
(oscillometric and manual sphygmomanometric) as compared to reference intra-arterial BP at 
different arterial locations, in AF and SR patients separately and in comparison. See figure 4 
for a flow-chart of the measurement procedure. Conventional systolic BP was similar in the 
AF compared to the SR group, whereas conventional diastolic BP was numerically higher 
(significantly for some comparisons) in AF compared to SR patients. Results regarding 





Table 5. Conventional BP measurement and bias in comparison to intra-arterial BP at 
different arterial locations. OBP indicates oscillometric blood pressure, MBP indicates 
manual auscultatory blood pressure. P indicates p-value. 
 
Measurement biases for conventional diastolic BP were overall small in absolute numbers, 
both in the AF and SR group. Regarding the accuracy of conventional systolic BP, 
measurement biases were however larger. In the SR group conventional BP measurement 
numerically underestimated reference intra-arterial systolic BP at all locations (significantly 
except for comparison to central BP). In the AF group conventional systolic BP, as in SR, 
numerically underestimated radial intra-arterial BP but in contrast to SR, oscillometric 
measurement numerically overestimated intraarterial brachial and central BP. In a 
comparison of conventional BP measurement bias between groups, oscillometric BP 
measurement in AF overestimated brachial intra-arterial BP by 14.1 mmHg (p<0.01) and 
central intra-arterial BP by 9.0 mmHg (p=0.01), in comparison to patients in SR. These 





Figure 12. Conventional systolic BP measurement bias in AF and SR. RRK (Riva-Rocci 
Korotkoff) indicates manual auscultatory BP measurement. 
 
 
Figure 13. Conventional diastolic BP measurement bias in AF and SR. RRK (Riva-Rocci 






6.1 BLOOD PRESSURE IN ATRIAL FIBRILLATION – WHY IS IT OF 
INTEREST? 
Atrial fibrillation has a high prevalence and is closely intertwined with hypertension.2,12 Both 
conditions carry an increased risk for cardiovascular morbidity and mortality.5,6 Hypertension 
is considered to be the leading risk factor for premature death world-wide.30,34 The risks and 
the benefits of therapeutic intervention in hypertension have been thoroughly studied and 
quantified. However, this body of scientific evidence is primarily based on randomized 
clinical intervention trials on patients with SR, studies from which patients in AF have been 
consistently excluded.11 As shown in the studies included in this thesis,70,86,87 as well as from 
other studies, atrial fibrillation may affect BP in several ways. Evidence drawn from 
interventional hypertension trials conducted on patients with SR, regarding optimal treatment 
of hypertension, may therefore not be generalizable to patients with AF. Despite adjusting for 
known cardiovascular risk factors, AF is independently associated with a two-fold increased 
risk of death,5,68 for which the underlying pathophysiological mechanisms are not fully 
understood. Here, suboptimal understanding, measurement and treatment of blood pressure in 
atrial fibrillation may play a part. This also makes the case for further research into this area 
and has been an overarching theme for this project. 
 
6.2 BEAT-TO-BEAT BLOOD PRESSURE VARIABILITY IN ATRIAL 
FIBRILLATION 
As previously described, heart rhythm in AF is irregular. As a hemodynamic consequence, 
there is an increased BP variability in AF compared to SR. Although this is a familiar 
phenomenon in clinical cardiology, it has previously only been scientifically described in a 
study from 1940 by Buchbinder and Sugerman.10 In that study, including eight patients with 
AF, large variations in beat-to-beat BP were observed, these results were however not 
systematically quantified. In study I we sought to invasively measure and quantify beat-to-
beat BP variability in a cohort of patients with sustained AF in comparison to a control group 
of patients with SR. In summary, systolic BP variability was roughly doubled and diastolic 
BP variability was approximately six times higher, in AF compared to SR patients.70 The 
exact underlying physiological mechanisms determining the level of BP change between 
beats were not directly addressed in the study. However, during the diastolic phase, arterial 
BP progressively falls towards zero until initiation of the following systolic ventricular 
ejection phase. Consequently, during a longer diastole, arterial BP falls further. At the same 
time, a long diastolic phase prolongs left ventricular filling time, resulting in increased stroke 
volume and blood pressure surge during the following systolic phase. Since there is an upper 
limit for left ventricle filling volume, there is theoretically also an upper limit for the systolic 
BP surge. In contrast, there is no lower limit (except zero) for how much diastolic BP may 
fall during a long enough R-R-interval. An intra-arterial BP tracing is presented in figure 14 
for illustration. Theoretically, these relationships may explain our finding of a more profound 
beat-to-beat BP variability for diastolic compared to systolic pressure and this would also 
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imply that increased rhythm irregularity, as well as bradycardia with long R-R-intervals, 
would in particular affect the level of diastolic BP variability. 
 
6.3 POSSIBLE IMPLICATIONS FOR BLOOD PRESSURE MEASUREMENT 
A single conventional office BP measurement in SR provides a systolic and a diastolic BP 
value. This may be perceived as an average systolic and diastolic BP during resting 
conditions since short-term BP fluctuations in regular rhythm can be expected to be small. As 
shown in study I, short-term BP variability in AF is increased. A conventional BP reading 
will not be able to account for these BP fluctuations, but instead will only, in a best-case 
scenario, provide an average systolic and diastolic BP for what is actually a range of varying 
blood pressures. Furthermore, BP variability in AF most likely leads to an increased inter- 
and intra-observer variation for auscultatory BP.88 It has been proposed that this problem may 
to some extent be mitigated by calculating the mean from triplicate BP measurements.89,90 
However, in study I we also show that maximum BP difference between consecutive beats is 
markedly higher in AF compared to SR patients, in particular for diastolic BP. These 
conditions, prevalent in AF, will not be reflected in conventional BP measurement, even if an 
average from triplicate measurements is calculated. 
 
6.4 POSSIBLE PATHOPHYSIOLOGICAL HEMODYNAMIC CONSEQUENCES 
Since the subject of possible negative effects from short-term BP variability in AF has not 
been specifically studied, a discussion on the topic becomes hypothetical. Hypertension is a 
fundamental risk factor for the development of atherosclerosis33 and elevated BP may also act 
as a trigger for plaque rupture and subsequent vascular events.91,92 As outlined above, 
conventional BP measurement in AF will not reflect pressure peaks or troughs (see figure 
14). One may hypothesize, that such occasional pressure peaks and troughs could have short- 





Figure 14. Intra-arterial BP recording from patient with AF. Dashed lines indicate possible 
mean and/or measured systolic and diastolic BP. 
 
Whether there is a causal connection between AF per se and atherosclerosis is unclear. These 
conditions share the same risk factors which makes causality difficult to study. However, 
several studies imply that endothelial dysfunction, which may be viewed as a precursor of 
atherosclerosis, may be induced by AF61,93,94 and that this process may be reversed by 
restoring SR.95 Inflammation is a fundamental component of atherosclerosis.96 Earlier studies 
suggest a bidirectional association between inflammation and AF,97,98 although it is uncertain 
if there is also causality. Furthermore, results from other studies have demonstrated an 
association between AF and increased atherosclerosis, measured as carotid intima-media 
thickness.99–101 There also appears to be an association between increasing AF burden with an 
increased burden of atherosclerosis.100  
Emerging evidence suggest an association between AF and acute coronary syndrome.102–104 
Systemic inflammation and platelet activation associated with AF has been proposed as 
drivers, linking AF with an increased risk for myocardial infarction.105 There has been a 
longstanding controversy around the so called J-curve phenomenon, referring to findings of a 
non-linear relationship between diastolic BP and cardiovascular outcomes.106 There is 
however consistent evidence suggesting that lowering diastolic BP <70 mmHg in 
hypertensive patients is associated with an increased risk for coronary events.107,108 The 
coronary arteries are perfused during diastole and the likely explanation to these findings are 
that patients with coronary artery disease have a poor coronary flow reserve, thus making 
them vulnerable to low diastolic perfusion pressures.109 In study I we show large beat-to-beat 
fluctuations for diastolic pressure in particular, meaning that for some heart beats, diastolic 
pressure was far below average diastolic pressure for that individual during that certain intra-
arterial BP-recording. This observation may provide yet another hypothetical 
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pathophysiological mechanism, linking sustained AF with an increased risk for coronary 
events. Interestingly, in a pooled analysis, AF was associated with an increased risk for 
myocardial infarction, despite the fact that AF patients harbored less coronary atherosclerosis 
at baseline.110 
Although not specifically studied, it is thus hypothetically conceivable that increased beat-to-
beat BP variability in AF patients, with profound pressure peaks and troughs not reflected in 
conventional BP measurement, may contribute in pathophysiological processes linking AF to 
an increased risk for atherosclerosis and atherosclerotic cardiovascular events. Such 
pathophysiological processes may include increased inflammation and endothelial 
dysfunction, as well as more direct hemodynamic BP-mediated effects possibly affecting 
plaque stability and impairing myocardial blood flow. 
 
6.5 POSSIBLE AUTONOMIC AND NEUROHORMONAL EFFECTS 
Physiological control of BP is complex and involves autonomic and neurohormonal 
mechanisms. The autonomous nervous system fundamentally influences the regulation of the 
cardiovascular system, both short- and long-term.111,112 Short-term it mainly acts by inducing 
vasoconstriction through increased sympathetic nerve activity (SNA), mediated through 
baroreflexes.111 With regard to long term effects it has been proposed that increased SNA 
may induce endothelial dysfunction, vascular hypertrophy and remodeling, left ventricular 
hypertrophy and is also associated with cardiovascular disease.113–116 There may be a 
bidirectional relationship between increased autonomic nerve activity and AF.117 Initiation 
and progression of AF may be induced by increased autonomic nerve activity117,118 and 
conversely, autonomic nerve activity may be affected by AF itself.119 In one study, irregular 
atrial pacing simulating AF resulted in a 70% increase in SNA compared to regular pacing.120 
This effect is believed to be mediated through arterial baroreflexes.120 In another study, the 
level of rhythm irregularity was correlated to the level of increase in SNA.121 As shown in 
study I, the irregular rhythm in AF results in rapid beat-to-beat changes in BP. The 
cardiovascular system strives to uphold a physiologically optimal BP in each moment. A 
physiological response to these rapid BP changes in AF could be an increase in SNA, 
mediated through arterial baroreflexes. Thus, hypothetically the BP fluctuations in AF may 
drive an increase in SNA, which may potentially have negative effects on the vasculature and 
on long-term cardiovascular risk in AF patients.  
AF is also associated with an increased activity of the renin-angiotensin-aldosterone system 
(RAAS) and a reduction in serum aldosterone after successful restoration of SR by ECV has 
been demonstrated.122–124 A reduction in the activity of both the sympathetic nervous system 
and the RAAS after restoration of SR may thus be correlated to a reduction in BP. Such a 
mechanism is congruent with our observation in study II and III of a reduction of diastolic BP 
after SR restoration. It is however incongruent with our findings of increased systolic BP 




6.6 HOW IS BLOOD PRESSURE AFFECTED BY ATRIAL FIBRILLATION? 
The effects of AF on short-term BP variability is discussed above, but does AF affect BP in 
other ways? Study II is a retrospective study in which BP-effects from AF, measured with 
conventional sphygmomanometry, was evaluated in a population with persistent AF 
undergoing ECV.86 In summary, systolic BP was 9 mmHg lower and diastolic BP was 3 
mmHg higher, in AF before ECV compared to in SR one week after ECV. Only a few other 
studies examining this particular subject exist. BPs in those studies were primarily measured 
with the oscillometric method (as 24-h ambulatory BP or office BP) and results are not 
entirely conclusive. In two smaller studies, including 18 and 12 patients respectively, patients 
undergoing ECV were examined with 24-h ambulatory BP after restoration of SR. Mean 
diastolic BP decreased from 74 to 70 mmHg125 and from 81.7 to 75.2 mmHg,126 whereas 
mean systolic BP remained unchanged in both studies. In a slightly larger study, 63 patients 
with restored SR after ECV were evaluated with automated office oscillometric BP. A 5 
mmHg decrease in diastolic BP and 4-5 mmHg increase in systolic BP was observed after SR 
restoration.90 In another study from the same group of researchers,127 54 hypertensive patients 
with persistent AF were evaluated with 24-h ambulatory BP, before and approximately a 
month after ECV. In 34 patients retaining SR at one month, mean systolic 24-h ambulatory 
BP increased by 5.1 mmHg, whereas mean diastolic 24-h ambulatory BP decreased by 2.4 
mmHg. The results from this latter study127 is in line with study III,87 in which 98 patients 
with persistent AF were investigated with 24-h ambulatory BP before and approximately one 
week after ECV. In 60 patients remaining in SR at the second 24-h ambulatory BP 
monitoring, a significant increase of systolic 24-h ambulatory BP by 5.6 mmHg and a 
decrease of diastolic 24-h ambulatory BP by 4.7 mmHg, was observed.  
Thus, although there is some heterogeneity in earlier results, our results add to the overall 
evidence, suggesting that systolic BP is lower and diastolic BP is higher in AF compared to 
SR, according to either auscultatory sphygmomanometric or oscillometric BP measurement. 
As a result, pulse pressure appears to be markedly lower in AF compared to SR. 
 
6.7 CONVENTIONAL BP MEASUREMENT ACCURACY IN AF 
Conventional BP measurement is usually performed either with the auscultatory 
sphygmomanometric technique or with an automated oscillometric device. There are a 
number of studies validating oscillometric measurement accuracy in relation to auscultatory 
sphygmomanometry in individuals with SR.128,129 Some similar studies have been conducted 
in patients with AF,72–75 with heterogenous results. The presence of AF may cause 
measurement bias also with the auscultatory technique and there is no universal reference 
standard for how to perform validation studies for automated oscillometric devices in AF 
patients.71 However, in a recent meta-analysis it was suggested that the oscillometric method 
had reasonable accuracy regarding systolic BP, but tended to slightly overestimate diastolic 
BP, in AF patients in comparison to auscultatory BP.11  
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Intra-arterial BP measurement is typically considered a superior method for reference BP. In 
study IV, oscillometric and auscultatory sphygmomanometric BP measurements were 
compared to peripheral and central intra-arterial BP, in patients with sustained AF, and in 
comparison to patients with SR. Overall, conventional BP measurement was accurate 
compared to intra-arterial BP for diastolic pressure, both in AF and SR. There was however 
more heterogeneity regarding the results for systolic BP. In the presence of AF, oscillometric 
BP measurement overestimated intra-arterial brachial and central BP (by 4.1 and 5.0 mmHg 
respectively) and with measurement bias for the SR group taken into account, by 14.1 and 9.0 
mmHg respectively. Only a few previous studies have investigated oscillometric BP 
monitoring in AF in relation to intra-arterial reference BP.89,130,131 These small studies used 
different methodologies, mainly included patients in an intensive care setting and used intra-
arterial radial BP as reference pressure. The results from a meta-analysis that included these 
invasive studies, suggest that oscillometric BP monitoring in AF underestimate systolic radial 
intra-arterial BP by 4.1 mmHg and overestimate diastolic radial intra-arterial BP by 6.1 
mmHg,11 which is similar to what has been reported for patients with SR.132 The 
methodological differences between previous invasive studies and study IV complicate 
comparisons. As in previous studies however, oscillometric BP measurement in study IV also 
underestimated systolic intra-arterial BP, to a similar extent in AF and SR. In contrast to 
previous studies, oscillometric BP monitoring was however very accurate in relation to intra-
arterial radial diastolic BP. The accuracy of conventional BP measurement in the presence of 
AF has, to our knowledge, not previously been evaluated in relation to intra-arterial brachial 
and central BP. Since study IV is a small, first study specifically investigating this issue, the 
results should be interpreted with caution. However, provided these results can be replicated 
in larger samples, the relatively large measurement biases observed for conventional systolic 
BP compared to intra-arterial brachial and central BP, in particular in comparison to systolic 
measurement bias in SR, would be of clear clinical significance. 
 
6.8 IS BLOOD PRESSURE IN ATRIAL FIBRILLATION DIFFERENT PER SE? 
In study II and III, diastolic BP was higher whereas systolic BP was lower in AF than after 
restoration of SR. As a result, pulse pressure was markedly higher in SR after ECV (11 
mmHg or 23% for auscultatory sphygmomanometry in study II and 10.4 mmHg or 25% for 
24-h ambulatory BP in study III). It is not possible from these studies to determine the 
underlying mechanisms for this observation. This pulse pressure difference could be related 
to hemodynamic conditions prevalent in AF, measurement bias that differs in AF and SR, or 
to a combination of such factors. Of note, in study IV, a substantial difference in pulse 
pressure between AF and SR patients could be observed also for intra-arterial BP (18.9 
mmHg or 33% for brachial intra-arterial BP), although this is an inter-individual comparison 
in contrast to the intra-individual comparisons made in study II and III.  
As discussed above, previously reported measurement biases for conventional BP in AF 
compared to SR are not of the magnitude to explain this observed difference in pulse 
pressure. One may consider two hypothetical patients and, in a scientifically unorthodox 
 
 35 
manner, apply and combine the results from study III and IV for a rough comparison. Patient 
1 (AF-AF) has an oscillometric BP of 120/80 mmHg in AF before ECV, “true” intra-arterial 
brachial BP is 116/80 mmHg (according to study IV). Since patient 1 remains in AF after 
ECV, oscillometric and intra-arterial BP are unchanged at follow-up. Patient 2 (AF-SR) has 
an identical BP in AF before ECV. In SR after ECV, oscillometric BP is 126/75 mmHg 
(according to BP-changes in study III) and “true” intra-arterial brachial BP is 136/75 mmHg 
(according to study IV). Hence, according to our results, oscillometric measurement bias 
cannot explain the observed difference in pulse pressure. On the contrary, this hypothetic 
calculation would imply that “true” pulse pressure difference is even larger than reflected 
from oscillometric measurements. Thus, one may hypothesize that BP in AF, as a result of 
the hemodynamic conditions associated with AF, may be inherently different compared to 
SR, as indicated by a large difference in pulse pressure. Consequently, BP in AF and SR may 
not be fully interchangeable entities. 
A number of mechanisms potentially affecting hemodynamic conditions and BP differently 
in AF and SR can be identified. Autonomic and neurohormonal effects that may be 
associated with AF are discussed above. Loss of synchronized atrial contraction, reduced left 
ventricular filling, stroke volume, cardiac output and contractility, as well as irregular cardiac 
activation and endothelial dysfunction are other factors associated with AF that may 
potentially affect BP.60–62,133–135 Heart rate, which is often elevated in patients with AF, may 
be another factor that could affect BP. During normal physiological conditions, heart rate and 
BP normally moves in tandem.136 In an exercise test for example, both heart rate and BP 
increases. The relationship between heart rate and BP during more unphysiological 
conditions, such as in AF, are more uncertain. In both study II and study III, a significant 
difference in heart rate between AF and SR was observed (80-82 bpm and 58 bpm 
respectively, in both studies). One study investigated relationships between different BP 
parameters and changes of heart rate, induced by right atrial pacing in patients undergoing 
cardiac catherization.137 An incremental increase of heart rate was not accompanied by 
significant changes in peripheral (brachial) systolic or diastolic BP. In the linear regression 
analysis performed in study III, change in systolic BP was not significantly correlated to 
change in heart rate, whereas a moderate correlation for change in diastolic BP and heart rate 
was observed. Although such a correlation does not prove a causal relationship, it implies that 
differences in heart rate in AF and SR may affect diastolic BP, consistent with shorter R-R-
intervals to allow for a drop in diastolic pressure.  
True BP at a certain arterial site at a certain point in time is defined by the forward pressure 
wave, physiological arterial properties and by the timing and amplitude of the reflected 
pressure wave.138 The timing and summation of reflected waves onto the forward wave is the 
main underlying mechanism resulting in the amplification of pulse pressure usually seen from 
central to peripheral arteries.139–141 This pulse pressure amplification phenomenon could be 
observed also in AF patients in study IV. However, as illustrated in figure 14, it is quite 
evident that beat-to-beat pulse pressure variability is clearly increased in AF, although this 
has not been specifically quantified. Hypothetically, the irregular rhythm in AF may alter the 
timing of reflected waves in comparison to regular SR, thereby also affecting pulse pressure 
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amplification and BP throughout the arterial tree. Although not specifically studied, such a 
phenomenon could contribute to the observation from study II-IV of a lower pulse pressure in 
AF compared to SR. 
 
6.9 OPTIMAL BLOOD PRESSURE IN ATRIAL FIBRILLATION 
Even when adjusted for known cardiovascular risk factors, patients with AF are at increased 
risk for cardiovascular morbidity and mortality.5,68 AF share most of its risk factors with other 
cardiovascular disease and since these may be difficult to fully adjust for, there is a risk of 
residual confounding in observational studies. Hence, AF may act as a surrogate marker for 
increased risk and it is uncertain if and to what extent AF per se, in a causative way increases 
cardiovascular risk.  
There are no randomized clinical trials investigating treatment of hypertension specifically in 
AF patients and patients with AF have been consistently excluded from prospective 
hypertension treatment trials.11 Furthermore, there is very limited data regarding BP available 
also from earlier prospective trials in patients with AF.142 However, indirect evidence may 
still be drawn from randomized studies specifically including patients with AF. In the 
AFFIRM trial,143 patients with AF were randomized to either a rhythm or a rate control 
strategy. In this study, striving for SR with a rhythm strategy was not beneficial over a rate 
control strategy in terms of mortality. A few other earlier studies were also unable to 
demonstrate superiority of a rhythm strategy over a rate control strategy.144,145 However, in 
the recent and large-scale EAST-AFNET 4 trial,13 AF patients with cardiovascular conditions 
randomized to an early rhythm-control therapy had a significantly lower risk of 
cardiovascular events (including a significant reduction in death from cardiovascular causes) 
compared to patients randomized to rate-control therapy. These latter results may imply that 
AF rhythm itself, could have a causal relationship to increased cardiovascular morbidity. The 
underlying mechanisms responsible for such a possible causative link are not known. 
However, AF-related effects on BP and BP measurement, may hypothetically play a part.  
Even though a large body of evidence exist regarding hypertension treatment goals in patients 
with SR, controversy still exist pertaining to optimal BP, in general and regarding different 
subgroups of patients.146 This may be exemplified by the discussions following the SPRINT 
trial.147 There are no randomized trials primarily exploring the topic of optimal BP done 
specifically in patients with AF. In a post-hoc analysis from the AFFIRM trial, a U-shaped 
relationship between BP and mortality in patients with a diagnosis of AF was found.148 The 
nadir, or optimal BP in relation to risk of death was 140/78 mmHg in that study. However, 
since many patients were in SR during long periods of time it is uncertain to which extent 
these findings truly reflect the relationship between BP and risk in patients with persistent or 
permanent AF. A few other retrospective and post-hoc studies have investigated this topic in 
cohorts of patients with a diagnosis of AF but also without separating rhythm (AF or SR) at 
the times of BP measurement.149–151 In summary, optimal BP level for patients with sustained 
AF is uncertain.2,12 In the latest 2018 guidelines on hypertension from the ESC,22 BP 
treatment goals are the same for AF patients as for most other patient subgroups (120-129/70-
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79 mmHg for individuals below the age of 65 and 130-139/70-79 mmHg for individuals 65 
years and older). There is no other specific mentioning of optimal BP in AF, but it is stated 
that additional BP measurement may be needed in patients with AF and that the manual 
auscultatory method is recommended. Furthermore, the question “What is the optimal 
method to measure BP in patients with AF?” is listed under “Gaps in the evidence”. In the 
recently published guidelines on AF from the ESC,64 there is similarly no mentioning of any 
subjects pertaining to AF-effects on BP or to BP measuring techniques in patients with AF. 
 
6.10 LIMITATIONS 
There are several limitations in relation to the studies included in this thesis. The number of 
individuals included in study I and IV was fairly low, in particular for the control group of 
patients with SR. As a consequence, it was not possible to analyze the data in terms of 
subgroups. Furthermore, the two groups (AF and SR) were not ideally matched and baseline 
differences between the groups may cause confounding. All patients in study I and IV had a 
clinical indication for a coronary angiography, which constitutes a selection bias. It should be 
expected that the prevalence of atherosclerosis and risk factors for atherosclerosis was higher 
in this population in comparison to an AF population in general. Such conditions may affect 
BP throughout the arterial tree and possibly also the level of beat-to-beat BP variability. Thus, 
it is uncertain to which extent the results from study I and IV are generalizable to all 
individuals with AF. Although study I and IV were prospective studies with a rigorous 
protocol for how BP measurements were performed, there was an aspect of time constraint 
since examinations were performed during an invasive procedure. This prohibited the use of 
even more thorough measurements, such as triplicate cuff measurements at each time, which 
would otherwise have been desirable. Furthermore, algorithms among different devices for 
oscillometric BP measurement may differ, and the results may therefore not be generalizable 
to other devices from other manufacturers. In study IV, a high number of comparisons were 
made, introducing a possibility of mass significance. However, since comparisons were of 
similar setup, it should still be possible to get insight from trends, such as when comparing 
BP measurements from different arterial locations.  
Study II was a retrospective analysis which comes with inherent limitations. 57 individuals 
were excluded due to missing data regarding rhythm and/or BP at follow-up. It is however 
unlikely that this constituted a systematic selection bias. BP measurements used in the study 
were obtained under routine clinical circumstances and it was not possible to ascertain to 
which extent they were performed in accordance with local guidelines for BP measurement.  
However, BP measurements were performed in the same setting, by the same staff and with 
the same method before and after ECV, which should make them comparable. Patients with 
an immediate relapse in AF after ECV were sometimes scheduled for a new ECV attempt 
right away, after optimization of medical therapy. These patients did therefore not attend a 1-
week follow-up and were not included in the study. Thus, the proportion of patients 
maintaining SR after ECV may therefore have been overestimated.  
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Study III was a prospective, multi-center study primarily evaluating BP with 24-h ambulatory 
BP monitoring. The validity of different techniques for BP measurement is uncertain for 
patients with AF, in particular for 24-h ambulatory BP monitoring. It can therefore not be 
excluded that systematic measurement bias may have influenced the results. As for study IV, 
measurement accuracy may also differ between automated oscillometric devices from 
different manufacturers. All patients in study III had a clinical indication for ECV due to 
persistent AF. This selection bias means that the results may not be generalizable to other 





Beat-to-beat BP-variability is higher in patients with persisting AF compared to patients with 
SR. Systolic beat-to-beat BP variability is approximately twice as high and diastolic BP 
variability is approximately six times as high in AF compared to SR. The increased beat-to-
beat BP variability in AF may have implications for conventional BP measurement accuracy 
and could hypothetically also be involved in the pathophysiology behind the increased 
cardiovascular morbidity and mortality seen in patients with AF.  
In patients with persistent AF undergoing ECV, systolic sphygmomanometric office BP as 
well as 24-h ambulatory BP increased whereas corresponding diastolic BP decreased after 
restoration of SR. These findings imply that systolic BP and pulse pressure is lower whereas 
diastolic BP is higher in AF compared to SR. Hypothetically, this difference indicate that BP 
in AF may be inherently different to BP in SR. 
Conventional (oscillometric and sphygmomanometric) BP measurement in patients with 
persisting AF was accurate in relation to peripheral and central intra-arterial BP regarding 
diastolic BP. Conventional BP was however insufficiently accurate in relation to peripheral 
and central intra-arterial BP regarding systolic BP. In particular for oscillometric BP 
measurement in comparison to intra-arterial brachial and central BP, and with measurement 
bias in SR patients taken into account. There was no significant difference in pulse pressure 
amplification between patients with AF and SR. 
AF is associated with increased cardiovascular morbidity and mortality, but it is unclear to 
which extent there is also a direct causal relationship. There are several possible underlying 
mechanisms potentially linking AF with worse cardiovascular outcomes. AF affects BP but it 
is still uncertain if this has relevant pathophysiological consequences. Irrespective of the 
underlying mechanisms, if BP is affected by the presence of AF as indicated in this thesis, 
these results may have important clinical implications. If BP is different in AF per se, sound 
evidence for how to manage BP and hypertension in patients with sustained AF is lacking. 
Our results naturally need to be validated in other studies. Arguably, the broader topic of BP 










8 CLINICAL IMPLICATIONS 
 
The ESC guidelines for atrial fibrillation and for hypertension recommend that treatment for 
hypertension in patients with AF should be no different from in patients with SR. The 2018 
ESC hypertension guidelines also state that additional BP measurement may have to be 
performed in patients with AF and that the manual auscultatory method is recommended. In 
study II there was a 40% increase in the number of patients with a hypertensive BP-level 
(≥140/90) that could be identified after restoration of SR. In study III there was also a higher 
proportion of patients with a hypertensive BP-level (≥135/80 according to mean daytime 
ambulatory BP) among those with restored SR compared to patients still in AF. These 
findings suggest that an increased attention to BP after restoration of SR is important in order 
to achieve an optimal treatment of BP.
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9 FUTURE PERSPECTIVE 
 
A number of very important research questions regarding AF and blood pressure in AF 
remain to be answered. More research is needed to elucidate if AF per se is causally linked to 
the increased cardiovascular morbidity and mortality observed in AF patients. Earlier studies 
have not been able to show that maintaining SR reduces mortality. However, in the recently 
published EAST-AFNET 4 trial, AF patients randomized to a rhythm strategy had a lower 
risk of cardiovascular outcomes, indicating that maintenance of SR may be beneficial in 
terms of morbidity and mortality. Hopefully, other prospective trials randomizing AF patients 
to a rate or rhythm control strategy will be conducted. As therapies for maintaining SR (AF 
ablation in particular) are improved, the opportunities for conducting such trials and for 
getting clear results will also improve. If such trials would also include thorough and repeated 
BP measurements, with specifications regarding rhythm for each measurement, it would 
potentially also provide important insights regarding the role of BP and cardiovascular 
outcomes in AF patients. 
It will be important to further study the underlying mechanisms linking AF with worse 
cardiovascular outcomes. Such mechanisms could include hemodynamic, neurohormonal, 
inflammation and endothelial effects from AF. Patients with persistent AF that undergo 
therapy such as ECV or ablation in order to restore SR, provide a suitable setting to further 
study such mechanisms.  
The studies in this thesis are hypothesis generating and point to a number of potentially 
important research topics. From a more mechanistic perspective, it would be of interest to 
further study the determinants of the level of beat-to-beat BP-variability in AF. No doubt, the 
degree of irregularity is important but other factors such as heart rate probably also play a 
part. Such a study could be very similar to study I but in addition to intra-arterial BP, the 
recording would also need to include a clear time-scale, which was unfortunately lacking in 
study I.  
The results from study II and III, indicating that BP may be inherently different in AF, may 
have important implications for management and treatment of hypertension in patients with 
AF. Existing evidence from large randomized hypertension intervention trials, conducted 
among patients with SR, may not be generalizable to patients with sustained AF. One 
possible way to study this would be retrospectively from a larger database. This would need 
to contain information on BP and of rhythm (AF or SR) at the time of BP measurement. 
Ideally, one would also want to be able to adjust for other patient characteristics and 
medication. It would also be desirable, but perhaps less feasible, to address this question in a 
large-size prospective study similar to study III, and with a long follow-up. A third way 
would be to conduct an invasive study. It may be feasible and ethically acceptable to perform 
a prospective study on patients with persisting AF, undergoing ECV or AF ablation, with 
intra-arterial BP-recording. Such a design would provide direct information on how rhythm 
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affects BP. Ideally, simultaneously performed conventional BP measurements would provide 
further data regarding measurement bias in AF compared to SR. 
Finally, despite there being a substantial number of patients with established AF and 
concomitant hypertension, there is very little evidence regarding optimal BP in this group of 
patients. The highest level of evidence would naturally be attained from a prospective clinical 
trial, randomizing patients with sustained AF to different BP-goals, similar to in the SPRINT-
trial. In lack of a randomized trial, important data could also be obtained from retrospective 
registries comprising information on cardiovascular and other outcomes. As discussed above, 
information on rhythm at the time of BP measurement is a prerequisite for such studies to 























10 SVENSK SAMMANFATTNING 
 
Bakgrund 
Förmaksflimmer (FF) är den vanligaste ihållande hjärtrytmstörningen av klinisk relevans. Det 
uppskattas att åtminstone 2.9% av den vuxna befolkningen i Sverige lider av FF. Förhöjt 
blodtryck (BT) – hypertoni är ännu vanligare. I en vetenskaplig rapport av Statens beredning 
för medicinsk och social utvärdering (SBU) från 2004, beräknades förekomsten av hypertoni 
i Sverige vara 27% i den vuxna befolkningen. Både FF och hypertoni är associerat med en 
ökad risk för kardiovaskulär sjukdom. Hypertoni räknas som den globalt ledande riskfaktorn 
för förtida död, likaså är förmaksflimmer associerat med en tvåfaldig ökning av risken att 
avlida i förtid. Båda dessa tillstånd kan således innebära ett stort lidande för drabbade 
patienter och innebär en stor belastning och kostnad för hälso- och sjukvården. Blodtryck, 
hypertoni och FF är nära sammankopplade. På befolkningsnivå utgör hypertoni den 
vanligaste riskfaktorn för att också utveckla FF. Omvänt påverkar förekomsten av ihållande 
FF blodtrycket på individnivå. Vid FF är hjärtrytmen oregelbunden till skillnad från normal, 
så kallad sinusrytm. Detta innebär en ökad blodtrycksvariabilitet från slag till slag vid 
ihållande FF, men möjligen påverkas BT även på andra sätt. Dessa förhållanden kan tänkas 
påverka tillförlitligheten hos vanligt förekommande metoder för att mäta BT, hos patienter 
med FF. De underliggande orsakerna till att FF är associerat med ökad dödlighet är 
ofullständigt klarlagda. Hypotetiskt kan FF-orsakad påverkan på blodtrycket och 
mätosäkerhet av BT vid FF spela in, men dessa områden är vetenskapligt undersökta i endast 
mycket liten utsträckning. 
 
Syfte 
Det övergripande syftet med studierna i denna avhandling var att undersöka hur förekomst av 
FF påverkar blodtryck och tillförlitlighet hos konventionella metoder för BT-mätning. På sikt 
kan sådan kunskap öka förståelsen för varför patienter med FF har ökad risk att drabbas av 
kardiovaskulär sjukdom, kunskap som kan leda till förbättrad behandling och prognos för 
denna stora patientgrupp. 
Syftet med studie I var att undersöka och kvantifiera BT-variabiliteten från slag till slag hos 
patienter med FF i jämförelse med patienter med sinusrytm. I studie II användes ett 
retrospektivt material för att undersöka hur blodtrycket förändras när sinusrytm återställs med 
hjälp av så kallad elkonvertering. Frågeställning i studie III var liknande studie II men denna 
studie var prospektiv och BT-mätning skedde med så kallad 24-timmars ambulatorisk 
blodtrycksmätning. I studie IV studerades dels hur förekomsten av FF påverkar blodtrycket i 
olika delar av artärträdet jämfört med hos patienter med sinusrytm, dels studerades 
tillförlitligheten hos konventionell blodtrycksmätning i jämförelse med intraarteriell mätning 




Metod och resultat 
I studie I rekryterades 33 patienter (21 med FF och 12 med sinusrytm) som var planerade att 
genomgå kranskärlsröntgen. I samband med kranskärlsröntgen mättes intra-arteriellt BT i 
arteria radialis (handleden), arteria brachialis (överarmen) och i aorta ascendens (stora 
kroppspulsådern invid hjärtat). Den huvudsakliga frågeställningen var BT-variabilitet vid FF, 
vilket definierades som medelskillnaden från slag till slag avseende systoliskt respektive 
diastoliskt BT. BT-variabiliteten var signifikant högre (p<0.001) hos patienter med FF 
jämfört med hos patienter med sinusrytm vid alla mätlokalisationer. Den systoliska BT-
variabiliteten var ungefär dubblerad (4.9 jämfört med 2.4 mmHg) och den diastoliska 
variabiliteten var cirka sex gånger högre (7.5 jämfört med 1.2 mmHg) hos patienter med FF i 
jämförelse med patienter i sinusrytm. 
Den retrospektiva studie II baserades på journaluppgifter. 487 individer med ihållande FF 
som genomgick elkonvertering i syfte att återställa sinusrytm studerades. Information 
avseende hjärtrytm och BT (mätt med vanlig teknik med manschett och stetoskop - så kallad 
auskultatorisk sphygmomanometri) från dagen före och en vecka efter elkonverteringen 
inhämtades. Det primära utfallsmåttet var BT-förändring hos patienter med bestående 
sinusrytm efter elkonvertering. I gruppen med bibehållen sinusrytm ökade det systoliska 
blodtrycket med 9 mmHg (p<0.001) medan det diastoliska blodtrycket sjönk med 3 mmHg 
(p<0.001). Andelen patienter med ett förhöjt BT (≥140/90 mmHg) ökade med 40% i denna 
grupp. 
Studie III hade ett liknande upplägg som studie II men denna studie var prospektiv och 
blodtryck mättes med 24-timmars ambulatorisk blodtrycksmätning. Det primära utfallsmåttet 
var blodtrycksförändring hos patienter med bestående sinusrytm en vecka efter 
elkonvertering. Hos 60 patienter med bestående sinusrytm ökade systoliskt 24-timmars 
medelblodtryck med 5.6 mmHg (p<0.001) medan diastoliskt 24-timmars medelblodtryck 
minskade med 4.7 mmHg (p<0.001). Som en konsekvens av detta ökade pulstrycket 
(skillnaden mellan systoliskt och diastoliskt BT) med 25% (10.4 mmHg). 
I studie IV undersöktes samma individer som i studie I. Konventionellt BT (auskultatorisk 
sphygmomanometri och automatisk oscillometri) mättes simultant med intra-arteriellt BT. 
Det första syftet var att studera hur det intra-arteriella blodtrycket förändras från centrala till 
perifera delar av artärträdet hos patienter med ihållande FF i jämförelse med patienter med 
sinusrytm. Det andra syftet var att undersöka tillförlitlighet och mätprecision vid 
konventionell blodtrycksmätning i jämförelse med intraarteriell mätning hos patienter med 
ihållande FF, och i jämförelse med patienter med sinusrytm. Blodtrycksförändringen längs 
artärträdet hos patienter med FF skiljde sig inte signifikant från hos patienter med sinusrytm. 
Konventionell BT-mätning hade god precision i jämförelse med intra-arteriellt BT avseende 
diastoliskt BT, både hos patienter med förmaksflimmer och sinusrytm. Däremot överskattade 
automatisk oscillometrisk BT-mätning det intraarteriella blodtrycket i arteria brachialis (4.1 
mmHg, p=0.07) och aorta ascendens (5.0 mmHg, p=0.04) hos patienter med FF. Med hänsyn 
taget till det uppmätta mätfelet vid sinusrytm överskattade automatisk oscillometrisk BT-
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mätning det intraarteriella blodtrycket i arteria brachialis med 14.1 mmHg (p<0.01) och aorta 
ascendens med 9.0 mmHg (p=0.01) hos patienter med förmaksflimmer. 
 
Slutsatser 
Blodtrycksvariabiliteten från slag till slag är ökad hos patienter med FF jämfört med 
sinusrytm. Resultaten i denna avhandling tyder på att det systoliska blodtrycket är lägre 
medan det diastoliska blodtrycket är högre vid FF jämfört med vid sinusrytm, vid mätning 
med auskultatorisk sphygmomanometri och oscillometrisk 24-timmars blodtrycksmätning. 
Som en konsekvens av detta är pulstrycket klart lägre vid FF. Blodtrycksförändringen från 
det centrala till det perifera artärträdet skiljer sig inte signifikant hos patienter med ihållande 
FF jämfört med patienter med sinusrytm. Resultaten i denna avhandling tyder på att 
konventionell blodtrycksmätning har hög tillförlighet i jämförelse med intraarteriellt 
blodtryck hos patienter med FF, avseende diastoliskt BT. Automatisk oscillometrisk BT-
mätning överskattade dock systoliskt intraarteriellt BT i arteria brachialis och aorta ascendens 
hos patienter med FF, speciellt med hänsyn taget till uppmätt mätfel vid sinusrytm. 
Förekomsten av förmaksflimmer hos en individ påverkar blodtrycket. Detta kan ha betydelse 
för tillförlitligheten hos konventionella metoder för BT-mätning och det är tänkbart att det 
också påverkar risken för kardiovaskulär sjuklighet hos patienter med FF. Effekter på 





This thesis would not have been possible without the support of many people. I would like to 
express my sincere gratitude to all colleagues, friends and family. 
Nils Witt, main supervisor. Thank you for steering this ship with always steady hands and for 
your friendship. You were always very supportive and kind, also when my questions were 
perhaps not the smartest ones. You have such an excellent knowledge regarding all the parts 
of the research process. When feed-back from you arrives, it is always with 100% quality.  
Jan Östergen, co-supervisor and former main supervisor. Thank you for accepting me as a 
PhD-student, for kindly sharing with your vast experience and for introducing me to the 
basics of research. Despite your many commitments you always had time for questions and 
instant high-quality feed-back. To me, it has seemed the day has much more than 24 hours for 
you. 
Petter Ljungman, co-supervisor. Thank you for your always very knowledgeable help and 
support, regarding research as well as other things. Your enthusiasm for research is inspiring. 
Thank you for your friendship and for many good laughs. 
Mårten Rosenqvist, co-supervisor, authority on atrial fibrillation and on many other things. 
Thank you for your always positive attitude, your wisdom and for all insightful contributions 
in this project. You always make research seem like a joyful experience. 
Per Tornvall, clinical research leader and prefect at KI SÖS. Thank you for your support in 
this project and for supporting research at the department in general. 
Raffaele Scorza, head of the Department of Cardiology since this spring. Congratulations to 
a very good start to what is probably a sometimes challenging job. 
Jon Erik Jonsson, boss, room-mate and life theoretician in one person. Thank you for all 
good talks, although I am not sure we have reached any conclusions yet. 
Johan Ärnlöv, my PhD mentor and friend from medical school. Thank you for having been a 
possible safety-net during this project. 
Christina Jägrén, good friend and colleague. Thank you for introducing me to the wonders 
of hypertension medicine and for your support all through this PhD-project. 
Helga Skuladottir, Sofia Klavebäck, Ellen Jacobson, Adam Gille, Fredrik Viberg and 
Caterina Gallo, my co-authors. Thank you for good team work and for your always positive 
attitude. 
Lis Kohlström, Runa Sundelin and Gun Wedeen, research nurses at the Department of 
Cardiology. Thank you for your invaluable help and support throughout this project. 
Linda Nilson, research biomedical scientist. Thank you for your support and hard work. 
 
48 
Anette Boban, chief secretary. For your help and support with all things, big and small. 
Colleagues at the Section for arrhythmia. For being good friends and such fun and 
dynamic colleagues. 
All my colleagues and friends at the Department of Cardiology and Södersjukhuset. 
Thank you for making this a very nice and interesting place to work! 
Colleagues at the expert group for cardiovascular disease. Thank you for teaching me a 
lot about interpreting science and how to apply it in practice. 
My friends. Thank you for being such fun, generous, interesting and good friends! I hope to 
see a lot more of you all from now on. 
Kristina, Bertil, Ida, Henrik, Hanna, Mattias and kids. Thank you for support and for all 
family gatherings with good wine and interesting conversations. 
Irene and Göran, my parents. Thank you for almost 50 years of constant support, love and 
enthusiasm. 
Tobbe, Anna and kids. Thank you for all good laughs and for not asking how my PhD-
project is progressing too often. 
Fabbe och Julle. Thank you for being Fabbe and Julle and for having made me take a break 
or two during this work. You are the best kids there is. 
Emma. Thank you for all your love, help and support during the work with this thesis. And 





1. Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 
2013;274(5):461-8. 
2. Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: Doubts and 
certainties from basic and clinical studies. Circ Res. 2018;122(2):352-68. 
3. Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and 
control. Circulation. 2016;134(6):441-50. 
4. Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide prevalence of 
hypertension: A systematic review. J Hypertens. 2004;22(1):11-19. 
5. Benjamin EJ, Wolf PA, D’Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of 
atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 
1998;98(10):946-52. 
6. Miyasaka Y, Barnes ME, Bailey KR, et al. Mortality trends in patients diagnosed with first 
atrial fibrillation: a 21-year community-based study. J Am Coll Cardiol. 2007;49(9):986-92. 
7. Lau YF, Yiu KH, Siu CW, Tse HF. Hypertension and atrial fibrillation: Epidemiology, 
pathophysiology and therapeutic implications. J Hum Hypertens. 2012;26(10):563-9. 
8. Huxley RR, Lopez FL, Folsom AR, et al. Absolute and attributable risks of atrial 
fibrillation in relation to optimal and borderline risk factors: The atherosclerosis risk in 
communities (ARIC) study. Circulation. 2011;123(14):1501-8. 
9. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence 
NETwork on Atrial Fibrillation: Patient characteristics and initial management. Europace. 
2009;11(4):423-34. 
10. Buchbinder WC, Sugarman H. Arterial blood pressure in cases of auricular fibrillation, 
measured directly. Arch Intern Med. 1940;66(3):625-42. 
11. Stergiou GS, Kyriakoulis KG, Stambolliu E, et al. Blood pressure measurement in atrial 
fibrillation: Review and meta-Analysis of evidence on accuracy and clinical relevance. J 
Hypertens. 2019;37(12):2430-41. 
12. Dzeshka MS, Shantsila A, Shantsila E, Lip GYH. Atrial Fibrillation and Hypertension. 
Hypertension. 2017;70(5):854-61. 
13. Kirchhof P, Camm AJ, Goette A, et al. Early Rhythm-Control Therapy in Patients with 
Atrial Fibrillation. N Engl J Med. 2020;383(14):1305-16. 
 
50 
14. Tanaka H, Heiss G, McCabe EL, et al. Hemodynamic Correlates of Blood Pressure in 
Older Adults: The Atherosclerosis Risk in Communities (ARIC) Study. J Clin Hypertens. 
2016;18(12):1222-27. 
15. Salvi P. Pulse Waves.; 2012. doi:10.1007/978-88-470-2439-7 
16. Chirinos JA, Segers P, Hughes T, Townsend R. Large-Artery Stiffness in Health and 
Disease: JACC State-of-the-Art Review. J Am Coll Cardiol. 2019;74(9):1237-63. 
17. Cavalcante JL, Lima JAC, Redheuil A, Al-Mallah MH. Aortic stiffness: Current 
understanding and future directions. J Am Coll Cardiol. 2011;57(14):1511-22. 
18. Kaess BM, Rong J, Larson MG, et al. Aortic stiffness, blood pressure progression, and 
incident hypertension. JAMA. 2012;308:875-81. 
19. Pierce GL. Mechanisms and Subclinical Consequences of Aortic Stiffness. Hypertension. 
2017;70(5):848-53. 
20. Westerhof N, Sipkema P, Bos GCV Den, Elzinga G. Forward and backward waves in the 
arterial system. Cardiovasc Res. 1972;6(6):648-56. 
21. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of Pulse Pressure Amplification in 
Arterial Hypertension. Hypertension. 2009;54(2):375-83. 
22. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for themanagement 
of arterial hypertension. Eur Heart J. 2018;39(33):3021-104. 
23. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of 
cardiovascular disease and death: A systematic review and meta-analysis. Lancet. 
2016;387(10022):957-67. 
24. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome 
incidence in hypertension.1. Overview, meta-analyses, and meta-regression analyses of 
randomized trials. J Hypertens. 2014;32(12):2285-95. 
25. Brunström M, Carlberg B. Association of blood pressure lowering with mortality and 
cardiovascular disease across blood pressure levels a systematic review and meta-analysis. 
JAMA Intern Med. 2018;178(1):28-36. 
26. Ogden LG, He J, Lydick E, Whelton PK. Long-term absolute benefit of lowering blood 
pressure in hypertensive patients according to the JNC VI risk stratification. Hypertension. 
2000;35(2):539-43. 
27. Whelton PK, Carey RM, Aronow WS, et al. 2017 
ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the 
Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A 
Report of the American College of Cardiology/American Heart Association Task Force on 
Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. 
 
 51 
28. Muntner P, Carey RM, Gidding S, et al. Potential US Population Impact of the 2017 
ACC/AHA High Blood Pressure Guideline. Circulation. 2018;137(2):109-18. 
29. Khera R, Lu Y, Lu J, et al. Impact of 2017 ACC/AHA guidelines on prevalence of 
hypertension and eligibility for antihypertensive treatment in United States and China: 
Nationally representative cross sectional study. BMJ. 2018;362:k2357. 
30. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. Lancet. 2015;386(9995):801-12. 
31. Burrello J, Monticone S, Buffolo F, et al. Is there a role for genomics in the management 
of hypertension? Int J Mol Sci. 2017;18(6):1131 
32. Sitia S, Tomasoni L, Atzeni F, et al. From endothelial dysfunction to atherosclerosis. 
Autoimmun Rev. 2010;9(12):830-4. 
33. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors 
associated with myocardial infarction in 52 countries (the INTERHEART study): case-
control study. Lancet. 2004;364(9438):937-52. 
34. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease 
and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A 
systematic analysis for the Global Burden of Disease Study 2010. Lancet. 
2012;380(9859):2224-60. 
35. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood 
pressure of at least 110 to 115mmHg, 1990-2015. JAMA. 2017;317(2):165-82. 
36. O’Brien E, Fitzgerald D. The history of blood pressure measurement. J Hum Hypertens. 
1994;8(2):73-84. 
37. Babbs CF. The origin of Korotkoff sounds and the accuracy of auscultatory blood 
pressure measurements. J Am Soc Hypertens. 2015;9(12):935-50. 
38. Muntner P, Shimbo D, Carey RM, et al. Measurement of blood pressure in humans: A 
scientific statement from the american heart association. Hypertension. 2019;73(5):e35-e66. 
39. Forouzanfar M, Dajani HR, Groza VZ, Bolic M, Rajan S, Batkin I. Oscillometric blood 
pressure estimation: Past, present, and future. IEEE Rev Biomed Eng. 2015;8:44-63. 
40. James GD, Gerber LM. Measuring arterial blood pressure in humans: Auscultatory and 
automatic measurement techniques for human biological field studies. Am J Hum Biol. 
2018;30(1). 
41. Myers MG. The great myth of office blood pressure measurement. J Hypertens. 
2012;30(10):1894-8. 




43. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure 
measurement in predicting mortality: The Dublin outcome study. Hypertension. 
2005;46(1):156-61. 
44. Niiranen TJ, Mäki J, Puukka P, Karanko H, Jula AM. Office, home, and ambulatory 
blood pressures as predictors of cardiovascular risk. Hypertension. 2014;64(2):281-6. 
45. White WB, Barber V. Ambulatory Monitoring of Blood Pressure: An Overview of 
Devices, Analyses, and Clinical Utility. Springer International Publishing. 2016:55-76. 
46. Pichler G, Martinez F, Vicente A, Solaz E, Calaforra O, Redon J. Pulse pressure 
amplification and its determinants. Blood Press. 2016;25(1):21-7. 
47. Roman MJ, Devereux RB, Kizer JR, et al. Central pressure more strongly relates to 
vascular disease and outcome than does brachial pressure: The strong heart study. 
Hypertension. 2007;50(1):197-203. 
48. Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of 
Central Versus Brachial Blood Pressure With Target-Organ Damage: Systematic Review and 
Meta-Analysis. Hypertension. 2016;67(1):183-90. 
49. Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. 
Prediction of cardiovascular events and all-cause mortality with central haemodynamics: A 
systematic review and meta-analysis. Eur Heart J. 2010;31(15):1865-71. 
50. Picone DS, Schultz MG, Peng X, et al. Discovery of new blood pressure phenotypes and 
relation to accuracy of cuff devices used in daily clinical practice. Hypertension. 
2018;71(6):1239-47. 
51. McEniery CM, Cockcroft JR, Roman MJ, Franklin SS, Wilkinson IB. Central blood 
pressure: Current evidence and clinical importance. Eur Heart J. 2014;35(26):1719-25. 
52. Sharman JE. Central pressure should be used in clinical practice. Artery Res. 
2014;8(4):121. 
53. Mitchell GF. Central pressure should not be used in clinical practice. Artery Res. 
2015;9:8-13. 
54. Cheng HM, Chuang SY, Wang TD, et al. Central blood pressure for the management of 
hypertension: Is it a practical clinical tool in current practice? J Clin Hypertens. 
2020;22(3):391-406. 
55. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and 
implications. Circ Arrhythm Electrophysiol. 2008;1(1):62-73.  




57. Heijman J, Voigt N, Nattel S, Dobrev D. Cellular and molecular electrophysiology of 
atrial fibrillation initiation, maintenance, and progression. Circ Res. 2014;114(9):1483-99. 
58. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: 
implications for management. Circulation. 2011;124(20):2264-74. 
59. Kaye DM, Silvestry FE, Gustafsson F, et al. Impact of atrial fibrillation on rest and 
exercise haemodynamics in heart failure with mid-range and preserved ejection fraction. Eur 
J Heart Fail. 2017;19(12):1690-7. 
60. Rodman T, Pastor BH, Figueroa W. Effect on cardiac output of conversion from atrial 
fibrillation to normal sinus mechanism. Am J Med. 1966;41(2):249-58. 
61. Wijesurendra RS, Casadei B. Atrial fibrillation: effects beyond the atrium? Cardiovasc 
Res. 2015;105(3):238-47. 
62. Daoud EG, Weiss R, Bahu M, et al. Effect of an irregular ventricular rhythm on cardiac 
output. Am J Cardiol. 1996;78(12):1433-6.  
63. Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Belanger AJ, Wolf PA. Independent 
risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. 
Jama. 1994;271(11):840-4.  
64. Task A, Members F, Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and 
management of atrial fibrillation developed in collaboration with the European Association of 
Cardio-Thoracic Surgery (EACTS). Eur Heart J. Published online 2020:1-126. 
doi:10.1093/eurheartj/ehaa612 
65. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with 
atrial fibrillation in the European Union, from 2000 to 2060. Eur Hear J. 2013;34(35):2746-
51. 
66. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation 
in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future 
prevalence. Circulation. 2006;114(2):119-25. 
67. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: 
Virchow’s triad revisited. Lancet. 2009;373(9658):155-66.  
68. Vermond RA, Geelhoed B, Verweij N, et al. Incidence of Atrial Fibrillation and 
Relationship With Cardiovascular Events, Heart Failure, and Mortality: A Community-Based 
Study From the Netherlands. J Am Coll Cardiol. 2015;66(9):1000-7.  
69. Lip GYH, Beevers DG. ABC of Atrial Fibrillation: History, epidemiology, and 
importance of atrial fibrillation. BMJ. 1995;311(7016):1361-3. 
70. Olbers J, Gille A, Ljungman P, Rosenqvist M, Ostergren J, Witt N. High beat-to-beat 




71. Stergiou GS, Palatini P, Asmar R, et al. Recommendations and Practical Guidance for 
performing and reporting validation studies according to the Universal Standard for the 
validation of blood pressuremeasuring devices by theAssociation for the Advancement 
ofMedical Instrumentation/European Society of Hypertension/International Organization for 
Standardization (AAMI/ESH/ISO). J Hypertens. 2019;37(3):459-66. 
72. Anastas ZM, Jimerson E, Garolis S. Comparison of noninvasive blood pressure 
measurements in patients with atrial fibrillation. J Cardiovasc Nurs. 2008;23(6):519-24 
73. Lamb TS, Thakrar A, Ghosh M, Wilson MP, Wilson TW. Comparison of two 
oscillometric blood pressure monitors in subjects with atrial fibrillation. Clin Invest Med. 
2010;33(1):54-62. 
74. Stewart MJ, Gough K, Padfield PL. The accuracy of automated blood pressure measuring 
devices in patients with controlled atrial fibrillation. J Hypertens. 1995;13(3):297-300. 
75. Jani B, Bulpitt CJ, Rajkumar C. Blood pressure measurement in patients with rate 
controlled atrial fibrillation using mercury sphygmomanometer and Omron HEM-750CP 
device in the clinic setting. J Hum Hypertens. 2006;20(7):543-5. 
76. Clark CE, McDonagh STJ, McManus RJ. Accuracy of automated blood pressure 
measurements in the presence of atrial fibrillation: systematic review and meta-analysis. J 
Hum Hypertens. 2019;33(5):352-64. 
77. Kollias A, Stergiou GS. Automated measurement of office, home and ambulatory blood 
pressure in atrial fibrillation. Clin Exp Pharmacol Physiol. 2014;41(1):9-15. 
78. Clark CE, McDonagh STJ, McManus RJ. Measurement of blood pressure in people with 
atrial fibrillation. J Hum Hypertens. 2019;33(11):763-5. 
79. Thomas MC, Dublin S, Kaplan RC, et al. Blood pressure control and risk of incident 
atrial fibrillation. Am J Hypertens. 2008;21(10):1111-6.  
80. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-
onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention 
For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-
9.  
81. Rahman F, Yin X, Larson MG, et al. Trajectories of risk factors and risk of new-onset 
atrial fibrillation in the framingham heart study. Hypertension. 2016;68(3):597-605. 
82. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of 
systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. 
Circulation. 2009;119(16):2146-52. 
83. Grundvold I, Skretteberg PT, Liestøl K, et al. Upper normal blood pressures predict 




84. Gorenek B, Pelliccia A, Benjamin EJ, et al. European Heart Rhythm Association 
(EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) 
position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society 
(HRS) and Asia Pacific Heart Rhythm Society (APHRS). Europace. 2017;19(2):190-225. 
85. Goette A, Kalman JM, Aguinaga L, et al. EHRA/HRS/APHRS/SOLAECE expert 
consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. 
Europace. 2016;18(10):1455-90. 
86. Olbers J, Jacobson E, Viberg F, et al. Systolic blood pressure increases in patients with 
atrial fibrillation regaining sinus rhythm after electrical cardioversion. J Clin Hypertens. 
2019;21(3):363-8. 
87. Olbers J, Östergren J, Rosenqvist M, et al. Changes in 24-h ambulatory blood pressure 
following restoration of sinus rhythm in patients with atrial fibrillation. J Hypertens. 
Published online 2020. doi:10.1097/hjh.0000000000002623 
88. Sykes D, Dewar R, Mohanaruban K, et al. Measuring blood pressure in the elderly: Does 
atrial fibrillation increase observer variability? Br Med J. 1990;300(6718):162-3. 
89. Pagonas N, Schmidt S, Eysel J, et al. Impact of atrial fibrillation on the accuracy of 
oscillometric blood pressure monitoring. Hypertension. 2013;62(3):579-84.  
90. Maselli M, Giantin V, Corrado D, et al. Reliability of Oscillometric Blood Pressure 
Monitoring in Atrial Fibrillation Patients Admitted for Electric Cardioversion. J Clin 
Hypertens. 2015;17(7):558-64. 
91. Li ZY, Taviani V, Tang T, et al. The mechanical triggers of plaque rupture: Shear stress 
vs pressure gradient. Br J Radiol. 2009;82 Spec No 1:39-45. 
92. White WB. Cardiovascular risk and therapeutic intervention for the early morning surge 
in blood pressure and heart rate. Blood Press Monit. 2001;6(2):63-72. 
93. Guazzi M, Arena R. Endothelial dysfunction and pathophysiological correlates in atrial 
fibrillation. Heart. 2009;95(2):102-6. 
94. Takahashi N, Ishibashi Y, Shimada T, et al. Atrial fibrillation impairs endothelial function 
of forearm vessels in humans. J Card Fail. 2001;7(1):45-54. 
95. Shin SY, Na JO, Lim HE, et al. Improved endothelial function in patients with atrial 
fibrillation through maintenance of sinus rhythm by successful catheter ablation. J Cardiovasc 
Electrophysiol. 2011;22(4):376-82. 
96. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 
2005;352(16):1685-95. 




98. Hu YF, Chen YJ, Lin YJ, Chen SA. Inflammation and the pathogenesis of atrial 
fibrillation. Nat Rev Cardiol. 2015;12(4):230-43. 
99. Chen LY, Foo DC, Wong RC, et al. Increased carotid intima-media thickness and arterial 
stiffness are associated with lone atrial fibrillation. Int J Cardiol. 2013;168(3):3132-4.  
100. Proietti M, Calvieri C, Malatino L, et al. Relationship between carotid intima-media 
thickness and non valvular atrial fibrillation type. Atherosclerosis. 2015;238(2):350-5. 
101. Willeit K, Kiechl S. Atherosclerosis and atrial fibrillation--two closely intertwined 
diseases. Atherosclerosis. 2014;233(2):679-81. 
102. Soliman EZ, Lopez F, O’Neal WT, et al. Atrial Fibrillation and Risk of ST-Segment-
Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis 
Risk in Communities (ARIC) Study. Circulation. 2015;131(21):1843-50.  
103. Soliman EZ, Safford MM, Muntner P, et al. Atrial fibrillation and the risk of myocardial 
infarction. JAMA Intern Med. 2014;174(1):107-14. 
104. Ruddox V, Sandven I, Munkhaugen J, Skattebu J, Edvardsen T, Otterstad JE. Atrial 
fibrillation and the risk for myocardial infarction, all-cause mortality and heart failure: A 
systematic review and meta-analysis. Eur J Prev Cardiol. 2017;24(14):1555-66. 
105. Violi F, Soliman EZ, Pignatelli P, Pastori D. Atrial Fibrillation and Myocardial 
Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms. J Am 
Heart Assoc. 2016;5(5):e003347. 
106. Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T. The J-curve phenomenon revisited 
again: SPRINT outcomes favor target systolic blood pressure below 120 mmHg. Blood Press. 
2016;25(1):1-3. 
107. Böhm M, Schumacher H, Teo KK, et al. Achieved diastolic blood pressure and pulse 
pressure at target systolic blood pressure (120-140mmHg) and cardiovascular outcomes in 
high-risk patients: Results fromONTARGET and TRANSCEND trials. Eur Heart J. 
2018;39(33):3105-14. 
108. Lip S, Tan LE, Jeemon P, McCallum L, Dominiczak AF, Padmanabhan S. Diastolic 
Blood Pressure J-Curve Phenomenon in a Tertiary-Care Hypertension Clinic. Hypertension. 
2019;74(4):767-775. 
109. Cruickshank JM. Coronary flow reserve and the J curve relation between diastolic blood 
pressure and myocardial infarction. Bmj. 1988;297(6658):1227-30. 
110. Bayturan O, Puri R, Tuzcu EM, et al. Atrial fibrillation, progression of coronary 
atherosclerosis and myocardial infarction. Eur J Prev Cardiol. 2017;24(4):373-81. 
111. Bruno RM, Ghiadoni L, Seravalle G, Dell’oro R, Taddei S, Grassi G. Sympathetic 
regulation of vascular function in health and disease. Front Physiol. 2012;3:284. 
 
 57 
112. Mancia G, Grassi G. The autonomic nervous system and hypertension. Circ Res. 
2014;114(11):1804-14. 
113. Grassi G, Arenare F, Pieruzzi F, Brambilla G, Mancia G. Sympathetic activation in 
cardiovascular and renal disease. J Nephrol. 2009;22(2):190-5. 
114. Gamboa A, Figueroa R, Paranjape SY, Farley G, Diedrich A, Biaggioni I. Autonomic 
Blockade Reverses Endothelial Dysfunction in Obesity-Associated Hypertension. 
Hypertension. 2016;68(4):1004-10. 
115. Dinenno FA, Jones PP, Seals DR, Tanaka H. Age-associated arterial wall thickening is 
related to elevations in sympathetic activity in healthy humans. Am J Physiol - Hear Circ 
Physiol. 2000;278(4):H1205-10. 
116. Greenwood JP, Scott EM, Stoker JB, Mary DASG. Hypertensive left ventricular 
hypertrophy: Relation to peripheral sympathetic drive. J Am Coll Cardiol. 2001;38(6):1711-
7. 
117. Linz D, Elliott AD, Hohl M, et al. Role of autonomic nervous system in atrial 
fibrillation. Int J Cardiol. 2019;287:181-8. 
118. Chen PS, Chen LS, Fishbein MC, Lin SF, Nattel S. Role of the autonomic nervous 
system in atrial fibrillation: Pathophysiology and therapy. Circ Res. 2014;114(9):1500-15. 
119. Linz D, Ukena C, Mahfoud F, Neuberger HR, Böhm M. Atrial autonomic innervation: 
A target for interventional antiarrhythmic therapy? J Am Coll Cardiol. 2014;63(3):215-24. 
120. Wasmund SL, Li JM, Page RL, et al. Effect of atrial fibrillation and an irregular 
ventricular response on sympathetic nerve activity in human subjects. Circulation. 
2003;107(15):2011-5. 
121. Segerson NM, Sharma N, Smith ML, et al. The effects of rate and irregularity on 
sympathetic nerve activity in human subjects. Hear Rhythm. 2007;4(1):20-6. 
122. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU. Effect of 
successful electrical cardioversion on serum aldosterone in patients with persistent atrial 
fibrillation. Am J Cardiol. 2001;88(8):906-9. 
123. Seccia TM, Caroccia B, Adler GK, Maiolino G, Cesari M, Rossi GP. Arterial 
Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. Hypertension. 
2017;69(4):545-50. 
124. Ehrlich JR, Hohnloser SH, Mattel S. Role of angiotensin system and effects of its 
inhibition in atrial fibrillation: Clinical and experimental evidence. Eur Heart J. 
2006;27(5):512-8. 
125. Sanders NA, Bertolone C, Jetter TL, et al. Restoring sinus rhythm results in blood 
pressure reduction in patients with persistent atrial fibrillation and a history of hypertension. J 
Cardiovasc Electrophysiol. 2012;23(7):722-6. 
 
58 
126. Olsen R, Amlie A, Omvik P. Twenty-four-hour ambulatory blood pressure monitoring 
in atrial fibrillation. Blood Press Monit. 2002;7(3):149-56. 
127. Maselli M, Giantin V, Franchin A, et al. Effect of restoring sinus rhythm in hypertensive 
patients with atrial fibrillation undergoing electrical cardioversion. Blood Press Monit. 
2016;21(6):335-9. 
128. Stergiou GS, Asmar R, Myers M, et al. Improving the accuracy of blood pressure 
measurement: The influence of the European Society of Hypertension International Protocol 
(ESH-IP) for the validation of blood pressure measuring devices and future perspectives. J 
Hypertens. 2018;36(3):479-87. 
129. Stergiou GS, Tzamouranis D, Protogerou A, Nasothimiou E, Kapralos C. Validation of 
the Microlife Watch BP Office professional device for office blood pressure measurement 
according to the International protocol. Blood Press Monit. 2008;13(5):299-303. 
130. Halfon M, Wuerzner G, Marques-Vidal P, et al. Use of oscillometric devices in atrial 
fibrillation: a comparison of three devices and invasive blood pressure measurement. Blood 
Press. 2018;27(1):48-55. 
131. Lakhal K, Ehrmann S, Martin M, et al. Blood pressure monitoring during arrhythmia: 
Agreement between automated brachial cuff and intra-arterial measurements. Br J Anaesth. 
2015;115(4):540-9. 
132. Picone DS, Schultz MG, Otahal P, et al. Accuracy of Cuff-Measured Blood Pressure: 
Systematic Reviews and Meta-Analyses. J Am Coll Cardiol. 2017;70(5):572-86. 
133. Yoshino S, Yoshikawa A, Hamasaki S, et al. Atrial fibrillation-induced endothelial 
dysfunction improves after restoration of sinus rhythm. Int J Cardiol. 2013;168(2):1280-5. 
134. Shapiro W, Klein G. Alterations in cardiac function immediately following electrical 
conversion of atrial fibrillation to normal sinus rhythm. Circulation. 1968;38(6):1074-84. 
135. Clark DM, Plumb VJ, Epstein AE, Kay GN. Hemodynamic effects of an irregular 
sequence of ventricular cycle lengths during atrial fibrillation. J Am Coll Cardiol. 
1997;30(4):1039-45. 
136. Mancia G, Ferrari A, Gregorini L, et al. Blood pressure and heart rate variabilities in 
normotensive and hypertensive human beings. Circ Res. 1983;53(1):96-104. 
137. Wilkinson IB, Mohammad NH, Tyrrell S, et al. Heart rate dependency of pulse pressure 
amplification and arterial stiffness. Am J Hypertens. 2002;15(1 Pt 1):24-30. 
138. Hickson SS, Nichols WW, Yasmin, et al. Influence of the central-to-peripheral arterial 




139. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in 
arterial hypertension: Experts’ opinion and review of the data. Hypertension. 2009;54(2):375-
83. 
140. Papakonstantinou E, Pikilidou M, Georgianos P, et al. Wave reflections and systemic 
vascular resistance are stronger determinants of pulse pressure amplification than aortic 
stiffness in drug-naïve hypertensives. Clin Exp Hypertens. 2020;42(3):287-93. 
141. Sibiya MJ, Norton GR, Booysen HL, et al. Aortic backward waves rather than stiffness 
account for independent associations between pulse pressure amplification and left 
ventricular mass in a young to middle-aged sample. J Am Soc Hypertens. 2017;11(6):350-8. 
142. Manolis A, Doumas M, Poulimenos L, Kallistratos M, Mancia G. The unappreciated 
importance of blood pressure in recent and older atrial fibrillation trials. J Hypertens. 
2013;31(11):2109-17. 
143. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm 
control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. 
144. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial 
fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77. 
145. Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-
control in persistent atrial fibrillation: The strategies of treatment of atrial fibrillation (STAF) 
study. J Am Coll Cardiol. 2003;41(10):1690-6. 
146. Verdecchia P, Reboldi G, Angeli F. The 2020 International Society of Hypertension 
global hypertension practice guidelines - key messages and clinical considerations. Eur J 
Intern Med. 2020;0953-6205(20)30346-0. 
147. Wright JT, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus 
standard blood-pressure control. N Engl J Med. 2015;373(22):2103-16. 
148. Badheka AO, Patel NJ, Grover PM, et al. Optimal blood pressure in patients with atrial 
fibrillation (from the AFFIRM Trial). Am J Cardiol. 2014;114(5):727-36. 
149. Böhm M, Brueckmann M, Eikelboom JW, et al. Cardiovascular outcomes, bleeding risk, 
and achieved blood pressure in patients on long-term anticoagulation with the thrombin 
antagonist dabigatran or warfarin: Data from the RE-LY trial. Eur Heart J. 2020;41(30):2848-
59. 
150. Minhas JS, Coles B, Mistri AK, et al. What is the optimal blood pressure level for 
patients with atrial fibrillation treated with direct oral anticoagulants? J Hypertens. 
2020;38(9):1820-8. 
151. Kim D, Yang PS, Kim TH, et al. Ideal Blood Pressure in Patients With Atrial 
Fibrillation. J Am Coll Cardiol. 2018;72(11):1233-45. 
 
